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CRP   C-reactive protein 
CVD   Cardiovascular disease 
FT4   Free thyroxin 
HbA1c  Glycosylated haemoglobin A 
HDL   High-density lipoproteins 
HL   Hepatic lipase 
IDL   Intermediate-density lipoproteins 
 4
LCAT   Lecithin-cholesterol acyl transferase 
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Norsk sammendrag 
Bakgrunn: Hypertriglyseridemi er en tilstand der fastende triglyserid (TG) verdier er 
forhøyet. Flere arvelige og ervervede faktorer kan føre til hypertriglyseridemi. Veldig 
høye TG verdier har vist å øke risikoen for hjerte- og karsykdom og akutt pankreatitt. 
Kombinasjonen av livsstilsendringer og medisinsk behandling er ofte nødvendig i 
behandlingen av pasienter med høye TG verdier. 
Mål: Denne studien ønsker å kartlegge ulike primære og sekundære årsaker til 
hypertriglyseridemi, i tillegg til å lage en beskrivelse av pasienter med alvorlig 
hypertriglyseridemi. Studien vil også beskrive hva slags behandling deltagerne fikk 
på Lipidklinikken, og effekten av denne behandlingen. I tillegg, forekomsten av 
hjerte- og karsykdom og akutt pankreatitt i denne studiepopulasjonen vil bli anslått.        
Studiepopulasjon og metode: Studien inkluderte 65 individer som var henvist til 
Lipidklinikken, Oslo Universitetssykehus-Rikshospitalet, i perioden 2002-2007. Alle 
hadde en målt fastende TG verdi ≥10 mmol/L i løpet av behandlingen på 
Lipidklinikken. Journalene deres ble brukt som en kilde til informasjon. 
Resultater: Av alle deltagerne hadde 28 pasienter en registrert primær diagnose som 
kunne forklare hyperlipidemien deres. Resten av pasientene hadde minst én sekundær 
diagnose i tillegg til hyperlipidemien deres. De fleste deltagerne brukte en eller flere 
lipidsenkende medisiner. TG og total-kolesterol verdiene var signifikant reduserte 
etter start av behandling. Totalt 19 deltagere hadde en medisinsk historie med hjerte- 
og karsykdom og 11 pasienter hadde opplevd pankreatitt. 
Konklusjon: Denne pasientgruppen er i en høy grad affisert av morbiditet. Medisinsk 
behandling, antakelig i kombinasjon med livsstilsendringer, førte til en bedring i 
deres lipidprofil. 
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English summary 
Background: Hypertriglyceridemia refers to a condition where fasting plasma 
triglyceride (TG) level is elevated. Several inherited and acquired factors can lead to 
hypertriglyceridemia. Very high TG values have shown to increase the risk for 
coronary heart disease (CHD) and acute pancreatitis. The combination of lifestyle 
changes and medication are often necessary in the treatment of patients with high TG 
levels.  
Aims: The present study aims to map different primary and secondary causes of 
hypertriglyceridemia, in addition to make a description of patients with severe 
hypertriglyceridemia. The study will also describe what kind of treatment the 
participants received at the Lipid Clinic, and the effect of this treatment. In addition, 
the prevalence of CHD and acute pancreatitis in the study population will be 
estimated.   
Study population and method: The study included 65 individuals who were 
referred to the Lipid Clinic, Oslo University Hospital-Rikshospitalet, in the period 
2002-2007. They all had a measured fasting TG level ≥10 mmol/L at some point 
during their treatment at the Lipid Clinic. Their medical journals were used as a 
source for information 
Results: Of all the participants, 28 patients had a registered primary diagnosis that 
could explain their hyperlipidemia. The remaining patients had at least one secondary 
diagnosis in addition to their hyperlipidemia. Most of the participants used one or 
several lipid-lowering medications. Their TG and total-cholesterol levels were 
significantly reduced after start of treatment. In total, 19 participants had a medical 
history of CHD and 11 patients had experienced pancreatitis. 
Conclusion:  This patient group is in a high degree affected by morbidity. Medical 
treatment, probably in combination with lifestyle alterations, led to an improvement 
in their lipid profile. 
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1. Background 
1.1 Hypertriglyceridemia 
Triglycerides (TG) are fatty substances which can be found in blood and in food that 
contain fat. In everyday language TG are what we call fat. The greatest sources for fat 
in the Norwegian diet are margarine and fat used in cooking, milk and dairy products, 
meat and meat products (1). Hypertriglyceridemia refers to a condition where fasting 
plasma TG level is elevated. Hyperlipidemia is a term which includes all forms of 
elevated blood lipids, while combined hyperlipidemia is a condition where both the 
TG and cholesterol levels are elevated. Factors contributing to elevated TG levels 
include overweight, pregnancy, excess alcohol intake, several diseases, drugs and 
genetic disorders (2). According to the World Health Organisation (WHO), 1.6 
billion adults were overweight in 2005. WHO further projects that approximately 2.3 
billion adults will be overweight by 2015 (3). With this increasing prevalence of 
overweight in the population, and its associated complications, one might expect that 
hypertriglyceridemia will become more customary, as well as complications due to 
this condition. Very high TG increase the risk not only for coronary heart disease, but 
also for acute pancreatitis (2;4). 
1.1.1 Clinical manifestations 
Hypertriglyceridemia may manifest clinically as eruptive cutaneous xanthomas, 
which appear as yellow eruptions 2-5 mm in diameter, often with erytematous areolae 
(figure 1). They will often appear in clusters on the skin of the trunk, buttocks or 
extremities. This manifestation is often associated with conditions with markedly 
elevated plasma chylomicrons in cases of familial chylomicronemia, or primary 
mixed dyslipidemia. Persons with hypertriglyceridemia have lipemic plasma. 
Lipemic plasma is blurred and not clear and transparent as ordinary plasma appears. 
When the plasma TG concentration exceeds 35 mmol/L one might see a milky 
appearance of the retinal vessels and a pink retina. This manifestation is called 
lipemia retinalis. Tuberous xanthomas, often moveable and nontender, may appear on 
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extensor surfaces in patients with type III hyperlipoproteinemia. In addition, 
hypertriglyceridemia might cause xanthoma striata palmaris which appear as 
yellowish deposits within palmar creases. These skin lesions are only seen in patients 
with type III hyperlipoproteinemia (5). 
 
Figure 1. Clinical manifestations of hypertriglyceridemia (5). 
A: Eruptive cutaneous xanthomas (here on a patient’s knee). B: Lipemic plasma. C: Lipemia retinalis. 
D: Tuberous xanthomas. E: Xanthoma striata palmaris  
 
1.1.2 Epidemiology of hypertriglyceridemia 
Various expert panels have made statements and recommendations during the last 
decades. The National Cholesterol Education Program in USA has divided fasting TG 
values into 4 different strata: normal (<1.69 mmol/L), borderline-high (1.69-2.25 
mmol/L), high (2.26 and 5.63 mmol/L) and very-high (>5.64 mmol/L) (6). TG values 
>10 mmol/L are considered as severely elevated (2). It is estimated that 2-3 % of the 
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American population have very high TG levels. However, less than 1 out of 5000 
persons have TG values above 10 mmol/L (4). Results from a study conducted in 
Norway in the period 1985-1999 among persons aged 40-42 years, showed that 3.9 % 
of the male and 0.57 % of the female study population had TG levels  >5 mmol/L. In 
addition, 0.25 % men and 0.037 % women had TG levels >10 mmol/L. (Anja Schou 
Lindman, National Public Health Institution, personal communication). 
1.2 Lipoprotein metabolism 
Fats are not soluble in water and are therefore transported in the blood in lipoprotein 
particles (7). Lipoproteins are a family of particles that can be divided into five 
classes by ultracentrifugation, from the least dense and largest to the most dense and 
smallest. These five classes are called chylomicrons (CM), very-low-density 
lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density 
lipoproteins (LDL), and high-density lipoproteins (HDL). The lipoproteins appear to 
function as an efficient mechanism for the transport of their core components, TG and 
cholesterol ester (CE), in the circulation (figure 2). In addition to these core 
components, they consist of an outer surface monolayer of phospholipids and free 
cholesterol, and each lipoprotein particle contains one or more protein molecules, 
called apolipoproteins (apo) (8). The CM and VLDL particles are often referred to as 
the TG-rich lipoproteins, and are mainly concerned with delivery of TG to tissues, 
mainly muscle and adipose tissue, for storage and use. LDL and HDL particles are 
more involved in the cholesterol transport to and from cells. IDL particles are 
catabolic products of CM and VLDL particles (9). More characteristics of the major 
lipoprotein classes are listed in table 1. 
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Figure 2. Schematic illustration of a lipoprotein particle (10). 
 
Table 1. Characteristics and functions of the plasma lipoproteins (7;11). 
 CM VLDL IDL LDL HDL 
Density g/ml <0.950 0.950- 1.006 1.006- 1.019 
 
1.019-1.063 1.063-1.210 
Origin Intestine Liver Plasma 
(from VLDL) 
Plasma 
(from IDL) 
Liver, 
intestine 
Physiologic role Transport of 
exogenous 
(dietary) TG 
Transport of 
endogenous 
TG 
LDL 
precursor 
Cholesterol 
transport 
Reverse 
cholesterol 
transport 
Half-life 6 min 1-12 hours ≈24 hours 60 hours 120 hours 
Composition (%)      
-TG 90 60 40 10 5 
-Cholesterol 5 10 30 50 20 
-Phospholipid 3 18 20 15 25 
-Protein 2 10 10 25 50 
Apolipoproteins A-I, IV 
B-48 
C-I, II, III 
B-100 
C-I, II, III 
E 
B-100 
E 
B-100 A-I, II 
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1.2.1 Intestinal fatty acid absorption and chylomicrons 
CM particles are TG-rich lipoproteins which are derived from dietary fat from the gut 
(8). After a meal, over 90 % of the TG concentration in plasma originate from the 
intestine and are found in circulating CM particles (5). The dietary intake of TG will 
normally account for the overall majority of TG input. Because of several meals per 
day, there will be a wide fluctuation of plasma TG levels throughout the day. Plasma 
TG levels should be determined after overnight fasting for comparison with normal 
values established in fasting normal populations (8).  
The metabolism of CM particles is often called the exogenous pathway of lipoprotein 
metabolism since it is the pathway for transporting fat which originates from our diet 
(9). TG from the diet are hydrolyzed into monoglycerides and free fatty acids by the 
aid of several lipases (mainly pancreas lipase). Together with bile acids the lipids 
make micellar configurations, and are then absorbed into intestinal cells probably by 
passive diffusion (7). If the fatty acids constitute ten carbon atoms or less they are 
absorbed as free fatty acids and pass into the portal circulation where they are carried 
directly to the liver. Long chain fatty acids are mainly absorbed as monoglycerides 
and are re-esterified into TG in the intestinal cells. The TG are assembled together 
with apo B-48 and apo A`s to form CM particles which pass into the thoracic duct. In 
the circulation the CM particles receive apo C-II from HDL particles (12). Following 
hydrolysis of TG in CM particles, by the action of an enzyme called lipoprotein 
lipase (LPL), apo C-II is released and again picked up by HDL particles (8). The CM 
particles have now lost some of their TG core as well as some unesterified 
cholesterol, phospholipids and apolipoproteins from their surface. The particles have 
become enriched in cholesterol ester and are called CM remnants. These remnants are 
transported to the liver where they are taken up by the cells via receptors, for instance 
by aid of the LDL-receptor related protein (9). The remnants may also be taken up by 
macrophages and consequently cause cholesteryl ester accumulation in these cells. 
This has been linked to the development of atherosclerosis (13). Figure 3 gives an 
overview of the lipoprotein metabolism. 
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Figure 3. Human lipoprotein metabolism (modified picture) (14) . 
 
1.2.2 Very-low-density lipoproteins 
The VLDL metabolism is called the endogenous pathway of lipoprotein metabolism, 
because TG- rich VLDL particles are synthesized and secreted from the liver (9). 
Endogenous TG predominate in the circulation during fasting (5). LPL will hydrolyse 
TG in VLDL particles. This contributes to the delivery of TG to extrahepatic tissues, 
in addition to surface material from VLDL to other particles, mainly HDL (8). The 
relatively cholesterol ester-enriched particles, which result after several cycles of 
lipolysis by LPL, may be taken up directly by a receptor in the liver and other tissues. 
This receptor is called the LDL receptor (LDLR) and binds a region in apo B-100 and 
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in apo E. Otherwise, the particles may remain in the circulation, and by the action of 
LPL and hepatic lipase (HL) they gradually continue to loose their contents of TG. 
Eventually, the resulting particles consist of a core enriched in cholesterol ester. They 
have lost all their surface components, except for apo B-100 and a layer of 
phospholipids and free cholesterol, and they have now become LDL particles (9). 
1.2.3 Low-density lipoproteins 
LDL is a cholesterol-rich particle which is removed from plasma by hepatic and 
extrahepatic tissues. LDL appears to be recognized by a specific high-affinity binding 
site present on the cell surface of tissues, namely the LDLR (13). Although expressed 
in most nucleated cells, the LDLR and the LDL uptake is particularly active in the 
liver (9). The bound lipoprotein is internalized by the cell in an endocytotic vesicle. 
The protein moiety of LDL is degraded, and the cholesterol esters, TG and 
phospholipids are hydrolyzed (13). The cellular cholesterol content is regulated by 
the SCAP-SREBP2 system. When the cellular cholesterol level is low, the cells up-
regulate the cholesterol synthesis and the expression of LDLR, and when the 
cholesterol content is high the opposite will happen (15). Scavenger receptors might 
also take up LDL particles. Different cells express these receptors, particularly 
macrophages, which are not subject for down-regulation like the LDLR (9).  
1.2.4 High-density lipoproteins  
HDL particles are secreted form the liver and intestine as pre-β HDL, and originally 
they contain only apo A-1 associated with some phospholipids. These particles 
acquire cholesterol by the interaction with other cells. In addition, they acquire 
surface material released during lipolysis of TG-rich lipoproteins. In this way the 
nascent HDL particles mature into cholesterol-rich particles. The metabolism of HDL 
and VLDL particles are closely linked. The HDL-cholesterol concentration is usually 
low when the TG concentration is high (9). 
There is a constant recycling of HDL particles between smaller, cholesterol-depleted 
(HDL3), and larger cholesterol- rich types (HDL2). The transport of cholesterol from 
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extrahepatic tissues and back to the liver is dependent on a membrane-associated 
protein, ABC-A1, and an enzyme that esterifies cholesterol, lecithin-cholesterol acyl 
transferase (LCAT). The HDL particles deliver their cholesterol to the hepatocytes 
via scavenger receptor-BI without itself being internalised. An alternative route is the 
transfer of cholesterol in HDL particles via the action of cholesterol ester transfer 
protein (CETP) to TG-rich particles (9). 
1.2.5 Lipoprotein lipase  
LPL is found in different tissues, particularly adipose tissue, skeletal muscle and heart 
muscle, where it is attached to endothelial cells of capillaries (9). It is synthesized 
within the cells of the tissue and will following secretion and transport to the capillary 
endothelial cell hydrolyse the TG in TG-rich lipoproteins. Released fatty acids are 
used by the muscle cells for metabolism and by the adipose tissue for re-synthesis and 
storage of TG. The enzyme is insulin sensitive, and a rise in insulin secretion 
following a meal will have a stimulating effect (8). 
1.2.6 Hepatic lipase 
HL is an enzyme present in the liver, which can hydrolyse both TG and cholesterol 
esters (9). However, HL prefers TG in remnant lipoproteins, in contrast to LPL which 
appears to prefer newly synthesized lipoprotein TG as substrate (8). 
1.2.7 Apolipoproteins 
There are nine major apolipoproteins involved in the lipoprotein metabolism: A-I, A-
II, A-IV, B (48 and 100), C-I, C-II, C-III, D and E. Apo A-I is an activator of LCAT. 
Apo B-48 is produced in the intestinal cells and is found in CM particles. Apo B-100 
is produced in the liver and incorporated into VLDL particles. LDL will also contain 
apo B-100. There is only one molecule of apo B present per particle, and they 
function as a ligand for receptors. Apo C-II is an activator of LPL (9), while apo C-I 
and C-III might inhibit the same enzyme. TG concentrations have shown to be 49 % 
higher in subjects with high Apo C-I and Apo C-III levels compared to those with 
low Apo C-I and Apo C-III levels (16). Apo E exists mainly in three isoforms: E2, 
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E3, E4, and an individual carries two alleles for this protein. This apolipoprotein is 
found on CM, VLDL and HDL particles, and serves as a ligand for receptors (9). 
1.3 Primary hypertriglyceridemia 
Hypertriglyceridemia can be divided into primary (inherited) and secondary 
(acquired) types. It can be difficult to distinguish between them because primary 
hyperlipidemias often are affected by other factors like diet, lifestyle and different 
medical conditions (2). 
1.3.1 Classification 
There are several ways to classify the different lipid disorders. The Fredrickson 
system of hyperlipidemia phenotypes is one of them, and has also been used in the 
present study (table 2). Five of the 6 Fredrickson types contain elevated TG levels as 
an essential diagnostic future (17). Another classification system is the International 
Classification of Diseases  (ICD-10) (18). This system is also widely used to 
distinguish between different disorders of the lipoprotein metabolism. 
1.3.2 Type I hyperlipoproteinemia  
Type I hyperlipoproteinemia in the Fredrickson system, also known as familial 
chylomicronemia, is characterized by severe fasting hypertriglyceridemia and 
massive accumulation of CM particles in plasma. The condition causes an initial 
manifestation during childhood (19). Chylomicronemia accompanied by eruptive 
xanthoma, lipemia retinalis and/or abdominal symptoms is referred to as the 
chylomicronemia syndrome, and can cause acute pancreatitis (20).  
Patients with the chylomicronemia syndrome usually have fasting TG levels greater 
than 10 mmol/L and the plasma TG concentration may even reach 100 mmol/L. Still, 
this condition does not seem to be associated with premature atherosclerosis (19). An 
explanation might be that the lipoprotein particles will be very large at such extreme 
TG levels, and consequently not able to penetrate the intima of arteries (21). 
However, some studies have identified peripheral and coronary atherosclerosis in 
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patients with familial chylomicronemia before the age of 55 years (22). CM particles 
are usually present in plasma after 12 hours fasting in subjects with chylomicronemia 
syndrome. Chylomicronemia is easily detected in a plasma sample because of the 
creamy appearance. The most common underlying molecular defect leading to 
familial chylomicronemia is LPL deficiency. This disorder is inherited as an 
autosomal recessive trait with a frequency in the general population of about 1 per 1 
million persons. The syndrome can also be caused by a familial deficiency of apo C-
II. This rare genetic disorder is also inherited as an autosomal recessive trait. The 
absence of apo C-II results in a functional deficiency of LPL. Patients with LPL 
deficiency present at an earlier age with more severe hypertriglyceridemia, and lower 
tolerance to dietary fat in comparison to patients with deficiency of apo C-II (19). A 
familial circulating plasma inhibitor of LPL might also lead to elevated CM levels in 
the plasma. Unlike the patients with LPL or apo C-II deficiency, this condition seems 
to be inherited as an autosomal dominant trait (23).  
1.3.3 Type IIa hyperlipoproteinemia 
This disorder is more known as familial hypercholesterolemia (FH), and is an 
autosomal dominant disorder. The condition is characterized by a high plasma 
concentration of LDL-cholesterol due to defects in the LDLR gene, tendon 
xanthomas and increased risk of premature coronary heart disease (CHD). In 
addition, some patients can have elevated levels of TG as a result of the interaction 
with other genes or environmental factors. However, the TG levels are usually in the 
normal range (24).  
1.3.4  Type IIb hyperlipoproteinemia 
Type IIb in the Fredrickson system, also called familial combined hyperlipidemia, is 
an autosomal dominant disorder. Still, no single gene has been identified as a 
causative factor (25). Type IIb hyperlipoproteinemia is considered as one of the most 
common genetic hyperlipidemias in the general population, with an estimated 
prevalence of 0.5-2.0 % (26).  
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Type IIb hyperlipoproteinemia is characterized by: (1) an increase in the cholesterol 
and/or the TG levels in at least two members of the same family, (2) intra-individual 
and intra-familial variability of the lipid phenotype, and (3) an increased risk of 
premature CHD (26). The lipid abnormalities in type IIb hyperlipoproteinemia are 
usually an increase of plasma TG and/or plasma cholesterol levels, elevated apo B, 
and small dense LDL particles. Despite a reduction in plasma TG concentrations, 
small dense LDL particles have been shown to persist in patients with this lipid 
disorder (27). Reduced levels of HDL-cholesterol are also a frequent finding in 
patients with type IIb hyperlipoproteinemia (26). The increase in circulating apo B 
and TG levels have been shown to be a result of an increased secretion of VLDL 
particles (28). However, other studies indicate that the causative factor is a reduced 
removal rate of TG from the plasma, due to a defective activity in enzymes like LPL 
(29). 
1.3.5 Type III hyperlipoproteinemia 
Type III hyperlipoproteinemia is also known as familial dysbetalipoproteinemia. This 
lipid disorder has a population prevalence of 1-2 in 20000 (5). The primary molecular 
cause of this lipid disorder is the presence of apo E2. Apo E2 differs from the most 
common isoform of apo E, namely apo E3, by a single amino acid substitution 
(cystein for arginine at residue 158). The disorder is associated with a recessive 
inheritance (30). Apo E plays a central role in the lipid metabolism by serving as a 
ligand for the binding of lipoproteins to lipoprotein receptors. The apo E2 variant is 
defective in binding to the LDLR (31). The disorder is characterized by elevated 
plasma cholesterol and fasting TG levels, usually to approximately equal levels. 
Accumulation of CM remnants and VLDL remnants, known collectively as β-VLDL, 
are the diagnostic hallmark of the disease. These lipoproteins are enriched with 
cholesterol, TG and apo E (30).  
Development of overt hyperlipidemia requires homozygosity for apo E2. 
Interestingly, less than 10 % of apo E2 homozygotes actually develop the 
hyperlipidemia. Additional genetic, hormonal or environmental factors are required 
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to give expression to the hyperlipidemia (30). In an analysis of 64 patients with type 
III hyperlipoproteinemia, 72 % were obese (BMI >25 kg/m2) and 14 % had diabetes 
mellitus, making these two conditions the most common additional factors in patients 
with familial dysbetalipoproteinemia (32). The risk of coronary artery disease has 
been found to be strikingly elevated in patients with type III hyperlipdemia, also after 
adjusting for other risk factors (33). In one study, 39 % of the patients with type III 
hyperlipidemia had atherosclerotic vascular disease (32). Peripheral vascular disease 
was more pronounced than both coronary artery disease and cerebrovascular disease.  
1.3.6 Type IV hyperlipoproteinemia 
Hyperlipoproteinemia type IV in the Fredrickson system is also known as familial 
hypertriglyceridemia. The condition is diagnosed according to the following criteria: 
(1) the patient has isolated hypertriglyceridemia, (2) isolated hypertriglyceridemia is 
also present in other family members, and (3) none of the family members suffer 
from any other dyslipoproteinemia. The condition is usually diagnosed in adults, and 
the inheritance is autosomal dominant (34). The disorder has an estimated prevalence 
of 1 % among adults of European descent (35). Type IV hyperlipoproteinemia is 
characterized by an elevation of VLDL particles, and the patients usually present with 
moderately elevated levels of TG and low levels of HDL-cholesterol. The molecular 
basis of this disorder is not solved. Familial hypertriglyceridemia is likely to be 
polygenic, requiring a secondary factor for expression. The condition is associated 
with increased CHD risk (17). 
1.3.7 Type V hyperlipoproteinemia 
Type V in the Fredrickson system, also called primary mixed hyperlipoproteinemia, 
is usually  characterized by elevated levels of both CM and VLDL particles (17). 
There is a pathologic presence of CM particles after a 12-14 hours period of fasting. 
The fasting TG measurements are typically >10 mmol/L. This condition usually 
manifests in adulthood, often together with other secondary factors. The population 
prevalence is about 1:1000 (5). The basic defects are still unknown. Patients with this 
primary hyperlipidemia have increased risk of coronary disease (34). 
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Table 2. Primary types of hypertriglyceridemia. 
Dyslipidemia Fredrickson 
phenotype 
ICD-10 Mechanism Lipoprotein 
abnormality 
Familial chylomicronemia Type I E78.3 LPL deficiency/ 
apo C-II deficiency 
↑ CM particles 
Familial 
hypercholesterolemia 
Type IIa E78.0 Defects in the 
LDLR gene 
↑ LDL particles 
Familial combined 
hyperlipidemia 
Type IIB E78.4 Basis unknown ↑ LDL and VLDL 
particles 
Familial 
dysbetalipoproteinemia 
Type III E78.2 Homozygous for 
apo E2 
↑ CM and VLDL 
remnants  
Familial 
hypertriglyceridemia 
Type IV E78.1  Basis unknown ↑ VLDL particles 
Primary mixed 
hyperlipidemia 
Type V E78.3  Basis unknown ↑ CM and VLDL 
particles 
 
1.4 Secondary hypertriglyceridemia 
Secondary hypertriglyceridemia is a condition caused by another primary disorder 
which has hypertriglyceridemia as a complication (35). Patients with 
hypertriglyceridemia usually have other lipid disorders as well, and they often have at 
least one contributing secondary factor (2). Those who develop secondary 
hypertriglyceridemia might have an underlying inherited defect which makes them 
susceptible for developing a lipid disorder (5). Table 3 gives an overview over 
different conditions that might lead to hypertriglyceridemia. 
1.4.1 Type 2 diabetes and insulin resistance 
Impairment in the ability of insulin to stimulate glucose uptake underlies type 2 
diabetes. In individuals who are insulin resistant, but have not yet developed type 2 
diabetes, hyperinsulinemia can be associated with other metabolic abnormalities, and 
together they compose the metabolic syndrome (5). Mild hypertriglyceridemia, with a 
low concentration of HDL-cholesterol, is a classic feature of insulin resistance and is 
a characteristic lipid profile in type 2 diabetes (36). In addition, the 
hypertriglyceridemia in diabetic patients is also associated with a raised concentration 
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of small, dense LDL particles in the plasma and a greater postprandial CM response 
(37).  
Insulin is an important hormone for the maintenance of normal adipose tissue LPL 
activity. Untreated diabetic patients appear to have a lower level of adipose tissue 
LPL, and this can be an important factor in the development of hypertriglyceridemia 
in these patients (38). Elevated levels of postprandial free fatty acids in plasma might 
also be one of the contributing factors that stimulate VLDL production in the liver 
(39). Together this can cause an elevation of TG in plasma.  
1.4.2 Obesity 
Obesity, especially central obesity, is often associated with several metabolic 
abnormalities, for instance hyperinsulinemia. Obese individuals might have up to 
three times higher postprandial TG levels than non-obese individuals (40). An 
abnormal postprandial lipid pattern is a trait of abdominal obesity even without 
fasting hypertriglyceridemia (41).  
1.4.3 Nonalcoholic fatty-liver disorder 
Excess liver fat has recently been recognized as the hepatic component in the 
metabolic syndrome. Fatty liver is closely related to other components of the 
metabolic syndrome, for instance dyslipidemia (42). In a study where two groups of 
patients were compared, the group with fatty liver showed several features of insulin 
resistance including fasting hyperinsulinemia, hypertriglyceridemia and low HDL-
cholesterol concentration, as compared with the patients without fatty liver (43). The 
increase in TG concentration is the major component of the dyslipidemia in fatty liver 
disorders. Studies have shown that this lipid abnormality is a result of increased 
production of large VLDL particles in the liver (44).  
1.4.4 Hypothyroidism 
Over 90 % of overtly hypothyroid patients have hyperlipidemia (45). Another study 
found that 14 % of 303 women with dyslipidemia showed sub-clinical 
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hypothyroidism, while 4 % had an overt hypothyroidism and 2.6 % were already 
under hormone replacement therapy (46). This shows that unrecognised 
hypothyroidism is common among dyslipidemic patients. O`Brien et al investigated 
the lipid profile of 268 patients with primary hypothyroidism and 27 patients with 
secondary hypothyroidism (47). Hyperlipidemia was commonly associated with both 
primary and secondary hypothyroidism. Total/ HDL- cholesterol and LDL/ HDL- 
cholesterol ratios were increased in both male and female patients, and they 
decreased with replacement of thyroid hormone. Other studies have shown that total-
cholesterol, HDL-cholesterol, TG, Lp (a), apo AI and apo B100 are increased in 
patients with hypothyroidism (48). These results are not entirely consistent with other 
studies. Lee et al found no significant differences in the concentration of Lp (a), 
HDL-cholesterol or apo A-I in persons with hyperthyroidism, hypothyroidism and 
controls (49). However, they did find that TG levels were significantly higher in 
patients with hypothyroidism compared to those with hyperthyroidism and healthy 
controls.  
The synthesis of plasma TG are found to be normal in patients with hypothyroidism, 
but the fractional removal of endogenous and exogenous TG are markedly reduced 
(50). Studies have shown that patients with overt hypothyroidism have decreased 
post-heparin plasma LPL activity, in addition to HL activity. LPL activity is usually 
increased by thyroid hormone, and patients with thyroid dysfunction may therefore 
develop hypertriglyceridemia as a consequence of changes in the activities of these 
enzymes (51). 
1.4.5 Renal disease 
Hyperlipidemia is a hallmark of the nephrotic syndrome. The hyperlipidemia is 
usually characterized by elevated cholesterol levels, although hypertriglyceridemia 
may be present as well. One hypothesis is that the hyperlipidemia is a result of an 
increase in the synthesis of proteins in the liver, including lipoproteins. However, this 
hypothesis has been rejected in later studies where it has been shown that VLDL apo 
B100 levels were primarily increased as a consequence of a decrease in fractional 
 30
catabolic rate rather than from an increase in absolute synthesis rate (52). In addition, 
the increase in TG level in nephrotic syndrome has been found to be a result of 
reduced clearance of TG-rich lipoproteins due to a decrease in the presence of 
endothelial-bound LPL, which occurs as a consequence of reduced serum albumin 
concentration, and a defect in VLDL binding to endothelial-bound LPL. The latter 
defect occurs only in the presence of proteinuria (53). 
1.4.6 Alcohol 
Studies of chronic alcoholics have shown that both the production and the catabolic 
rate of VLDL-TG were significantly increased compared to a control group of non-
alcoholic men. This accelerated catabolism of VLDL might also be responsible for 
the elevated level of HDL observed in regular alcohol users (54). Plasma TG 
concentration might also be within the normal range in some alcohol users because of 
an adaptive increase in lipolytic activity (5). However, ethanol has usually shown to 
reduce TG clearance from the plasma, probably due to an inhibition of plasma LPL 
(55). 
Studies have shown that a daily intake of alcohol (average 160 g/day) affects both the 
concentration and composition of fasting and postprandial plasma lipoproteins (56). 
On the third day of daily alcohol administration, the average concentration of plasma 
TG was 68 % higher compared to baseline. Alcohol enhanced the postprandial rise of 
TG in all lipoprotein fractions. Whether alcohol consumption per se increases TG 
concentration in patients with established hypertriglyceridemia is more unclear than 
the role of alcohol consumption on TG levels in normolipidemic individuals. In one 
study, where the mean TG values were 4 mmol/L and 1 mmol/L for the 
hypertriglyceridemic and non-hypertriglyceridemic groups respectively, the groups 
differed in TG response despite similar alcohol feeding (57). The participants were 
advised to fast for 12 hours before they consumed 30 g ethanol, followed by another 
10 hours of fasting. Six hours after the alcohol consumption the TG concentration 
increased with only 3 % in the hypertriglyceridemic group, and with 53 % in the non-
hypertriglyceridemic group. The study concluded that acute alcohol intake alone is 
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not an important determinant of plasma TG concentration in individuals with 
hypertriglyceridemia. 
1.4.7 Pregnancy 
During the third trimester of pregnancy plasma TG levels normally increase between 
two- and four-fold, while plasma cholesterol levels rise by approximately 50 %. 
Plasma lipid levels normally rise as a result of estrogen-induced hepatic production of 
TG-rich lipoproteins (58). In addition, it has been reported of an increase in HL 
activity and a decrease in LPL activity during pregnancy. The net effect will be an 
increase in circulating TG in plasma (59). This adaptation in the lipid metabolism 
might be beneficial and serve as extra energy for the mother, provide steroid hormone 
precursors for the placenta, and provide cholesterol and essential fatty acids for the 
fetus (60). 
Severe hyperlipidemia is a rare complication of pregnancy (58). Although 
hyperlipidemic pancreatitis in pregnancy is a rare event, patients with pre-existing 
abnormalities in the lipid metabolism may develop gestational hyperlipidemic 
pancreatitis. Fredrickson`s type I, IV and V hyperlipoproteinemias have been most 
commonly associated with acute pancreatitis in pregnancy (61). The risk of maternal 
and fetal mortality as a result of gestational pancreatitis is approximately 20 % each 
(62). 
1.4.8 Other medical conditions 
Autoimmune disorders, like systemic lupus erythematosis, might lead to an elevation 
in the plasma TG level (63). Several studies have also found a significant association 
between hyperuricemia (gout) and hypertriglyceridemia (64). The TG concentration 
may also be elevated in liver diseases, particularly cholestasis. The circulating 
lipoproteins can be present in abnormal amounts, in addition to have abnormal 
compositions (65). 
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1.4.9 Medications 
Different drugs might influence the lipid metabolism and increase the plasma TG 
concentration. One example is protease inhibitors which have several side-effects like 
lipodystrophy, insulin resistance and hyperlipidemia (66). The use of diuretics has 
also been shown to result in increased TG levels (67). In addition, medications like 
corticosteroids, estrogens and resins have been associated with adverse effects on the 
TG level (5). 
1.4.10 Diet 
Based on a typical Western diet, most people consume meals at regular intervals, 
where each meal contains 20-70 g fat (68). After consumption of a fat-containing 
meal, circulating TG show an increase after 1 hour, a peak after 2-3 hours and can 
remain high for 5-7 hours (69). Each meal following breakfast is most likely 
consumed before the plasma TG level has returned to the baseline value. Thus, 
humans spend most of their day-time in a postprandial fed state (68). 
Different nutrients may contribute to inter-individual variability in the postprandial 
lipemia (table 4). The amount of energy, the composition of a previous meal and meal 
frequency can be factors influencing the postprandial lipid response. In addition, 
postprandial lipemia is influenced by the amount and type of dietary fat, as well as 
carbohydrates (68). A low dose (15 g) of dietary fat in a meal has been shown not to 
increase the postprandial TG concentration in CM particles (69). However, intake of 
meals containing 30 g fat and up to 50 g fat led to a stepwise increase in the 
postprandial TG concentration in CM particles. In addition, replacement of saturated 
fatty acids with monounsaturated fatty acids in test meals have shown not to affect 
the postprandial metabolism of TG-rich lipoproteins (70). However, omega-3 
polyunsaturated fatty acids from fish oil lower the postprandial TG response if 
sufficient amounts are given in the test meal (71). 
Clinical studies indicate that diets rich in highly digestible carbohydrates can lead to 
high levels of fasting plasma TG (72). Parks et al conducted a study where they 
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compared subjects who were either normolipidemic or hypertriglyceridemic on both a 
control and a low-fat/high-carbohydrate (LF/HC) diet (73). The study diets differed in 
their percentage of energy from fat and carbohydrate. In addition, the LF/HC diet 
contained 50 % more fibre and 89 % less cholesterol than the control diet. The 
LF/HC diet resulted in a 60 % increase in TG, a 37 % reduction in VLDL-TG 
clearance and 18 % reduction in whole body fat oxidation, but no significant change 
in VLDL-apo B-48 or VLDL-TG secretion rates. Fasting de novo lipogenesis was 
low in both groups regardless of diet. However, other studies have found that a high 
carbohydrate diet leads to an increase in plasma VLDL-TG due to both an increase in 
hepatic VLDL-TG secretion rate and a reduced catabolism of VLDL-TG (74). 
Moreover, the amount and nature of carbohydrates in a meal can alter postprandial 
lipid metabolism. In one study the addition of glucose to a fatty test meal did not 
induce significantly alterations in postprandial lipemia, while the addition of sucrose 
or fructose markedly increased the postprandial triglyceridemia (75).  
Studies indicate that soluble viscous fibre might cause a reduction in the secretion of 
chylomicrons into the circulation, possible because they reduce the rate of digestion 
of dietary fats, and thereby attenuates the postprandial lipemic response (76). Very 
little information is available considering the influence of protein intake on 
postprandial lipid response. However, there is evidence indicating that soy protein 
might have a TG lowering effect. One study found a significant reduction in the TG 
level with 13.4 % in men who had eaten a diet with soy protein isolate for 3 weeks 
(77). 
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Table 3. Secondary conditions that might lead to hypertriglyceridemia. 
Secondary conditions Lipid abnormality Proposed mechanism 
Type 2 diabetes,  
insulin resistance, obesity 
↑ TG, ↓ HDL-cholesterol, 
↑ small dense LDL particles  
↑ TG production,  
↓ TG removal  
Fatty liver ↑ TG, ↓ HDL-cholesterol 
 
↑ VLDL  production 
Hypothyroidism ↑TG 
 
↓ TG removal  
Renal disease ↑ TG, ↑ total-cholesterol 
 
↓ TG removal  
Pregnancy ↑ TG, ↑ total-cholesterol ↑ VLDL production and/or  
↓ removal  
Medications  
(ex. protease inhibitors) 
↑ TG, ↑ total-cholesterol,  
↑ LDL-cholesterol 
↑ VLDL production and/or  
↓ removal  
Alcohol ↑ TG ↑ production and  
↓ removal of VLDL-TG  
 
 
Table 4. Dietary factors affecting the TG levels. 
Dietary factors Extent of effect on the postprandial lipemia 
Amount of fat +++ (Dose-dependent: 30-50 g/meal) 
Type of fat +/- (n-3 fatty acids have a lowering effect) 
Carbohydrates ++ (Diets rich in highly digestible carbohydrates) 
Protein No/- (Soy protein might have a reducing effect) 
Fibre No/- (Soluble viscous fibre have shown a reducing effect) 
+++, very important; ++, important; +, moderate increase; -, moderate reduction; No, no noticeable change 
 
1.5 Medical treatment of hypertriglyceridemia 
Four principally different groups of lipid-lowering medications are at the moment 
approved in Norway: statins, niacin, omega-3 fatty acids (fish oil) and resins (78). 
However, only the first three of them are the main pharmacologic agents for 
managing hypertriglyceridemia (79). Fibrates are also a group of lipid-lowering 
medications, but these are not marketed in Norway, although they are available. 
These different groups of lipid-lowering medications have somewhat different effects 
on the lipid levels (table 5).  
The treatment strategy for elevated TG depends on the cause of the elevation and its 
severity. In patients with secondary hypertriglyceridemia it is important to treat the 
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primary condition first (2). For persons with borderline-high or high TG levels, the 
primary aim of therapy is to achieve the target goal for LDL-cholesterol (2.6 mmol/L 
for patients with CHD). For patients with high TG levels, non-HDL-cholesterol 
(LDL+VLDL-cholesterol) becomes a secondary target of therapy (non-HDL-
cholesterol goal: 3.4 mmol/L for patients with CHD) (6). For persons with borderline-
high TG levels therapeutic lifestyle changes are often sufficient, in patients with high 
TG levels, drug therapy should be considered in addition. Statins with TG-lowering 
properties are first line agents for patients who have not reached their LDL-
cholesterol goal. In patients with high TG levels, who have reached their LDL-
cholesterol goal, a fibrate, niacin or fish oil can be considered. Some patients might 
also require a combination therapy to reach their LDL-cholesterol and non-HDL-
cholesterol goals. Patients with very-high levels will usually require drug therapy in 
addition to therapeutic lifestyle changes. Fibrates or niacin is often a first-line choice 
for these patients (79). The initial aim of therapy in patients with very-high TG levels 
is to prevent acute pancreatitis through TG lowering (6). 
1.5.1 Statins 
Atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin and simvastatin 
constitute a group of medications called statins. Statins inhibit hydroxymethylglutaryl 
coenzyme A-reductase (HMG-CoA-reductase), the rate limiting enzyme in 
cholesterol biosynthesis. Inhibition of this enzyme leads to reduced cholesterol 
synthesis and therefore a reduced hepatic cholesterol content. This results in an 
increase in the expression of LDL-cholesterol receptors (78). This up-regulation 
lowers the concentration of TG-rich lipoproteins in plasma because IDL and VLDL 
remnants are removed from the circulation via these receptors (13). Compared with 
placebo, atorvastatin has shown to significantly decrease the concentration of total-
cholesterol, TG, LDL-cholesterol and VLDL-apo B (80). In addition, the 
Scandinavian Simvastatin Survival Study (4S) showed that long-term treatment with 
simvastatin was safe and improved survival in CHD patients (81). 
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1.5.2 Fibrates 
The effect of fibrates is mediated through alterations in the transcription of genes 
encoding for proteins that control the lipoprotein metabolism. Fibrates activate the 
nuclear receptors termed the peroxisome proliferator-activated receptors (PPAR), 
which bind to specific response elements on DNA and alter the transcription rate of 
target genes. Of the different PPARs, the PPARα form is predominantly expressed in 
the liver and mediates fibrates action on lipoproteins. The effects of fibrates are: (1) 
induction of lipoprotein lipolysis due to an induction of LPL expression, (2) induction 
of hepatic fatty acid uptake and reduction of hepatic TG production, (3) induction of 
alterations in the plasma LDL composition and structure, which results in the 
formation of LDL with a higher affinity for the LDLR, and hence increased removal 
of LDL particles (82). 
In patients with type IIa, IIb and type IV hyperlipoproteinemia, fibrates have shown 
to cause a decrease in both total-cholesterol, LDL-cholesterol, plasma VLDL levels 
and an increase in HDL-cholesterol (83). In addition, fibrates can lead to an 
improvement in postprandial lipemia, which is likely due to LPL mediated 
enhancement of lipolytic hydrolysis (84). Fibrate therapy has been shown to decrease 
the risk of cardiovascular events in patients with cardiovascular disease (secondary 
prevention) (85).  
1.5.3 Niacin 
The primary action of niacin is to inhibit the mobilization of free fatty acids from 
peripheral tissues, thereby reducing hepatic synthesis of TG and secretion of VLDL 
particles (86). In pharmacologic doses, niacin reduces the concentration of total-
cholesterol, LDL-cholesterol, TG, VLDL, Lp (a), and increases the HDL-cholesterol 
(87). Concerns over worsening glycemic control have led to discouraging the use of 
niacin in treatment of patients with diabetes. However, a study of patients with and 
without diabetes taking lipid-lowering doses of niacin, demonstrated that niacin could 
be safely used in patients with diabetes without significantly affecting the glycemic 
control, in addition to exert beneficial effects on the lipid levels (88). Results from the 
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Coronary Drug Project Study reported that treatment with niacin reduced the rate of 
nonfatal myocardial infarction and the total 15-year mortality rate with 11 % 
compared with the placebo group (89).  
The use of niacin is limited because of adverse effects including flushing and 
gastrointestinal symptoms. Three different niacin formulations are currently 
available: immediate release, extended release and long acting. Almost all patients 
who use immediate release niacin will experience cutaneous flushing at the start of 
therapy. The long acting niacin is associated with a lower incidence of flushing. 
However, gastrointestinal and hepatotoxic side effects are more common and severe 
with this type of niacin. The use of extended release preparations have shown to 
result in less flushing and less risk of hepatotoxic effects compared with the two other 
niacin formulations (90).  
1.5.4 Fish oil 
Fish oil contains high amounts of the long omega-3 fatty acids termed 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) (79). Fish oils can be 
used alone in treatment of hypertriglyceridemia, or in combination with for instance 
statins in the treatment of combined hyperlipidemia (78). The proposed mechanisms 
for their TG-lowering effect are increased fatty acid oxidation, decreased TG 
synthesis and/or decreased VLDL cholesterol secretion (91). Patients with 
hypertriglyceridemia should receive 2-4 g of total EPA/DHA per day. Among 
different preparations which contain omega-3 fatty acids, Omacor is a highly 
concentrated form of omega-3-acid ethyl esters, and is also an approved medication 
for patients with hypertriglyceridemia (79). A systematic review showed that omega-
3 fatty acids are effective in lowering TG levels in a dose-dependent manner. The 
effects of omega-3 fatty acids on other plasma lipids were weaker (92). The GISSI-
Prevenzione trial found that treatment with omega-3 fatty acids significantly lowered 
the risk of primary endpoints (death, nonfatal myocardial infarction and stroke) (93). 
In contrary, a systematic review  showed no strong evidence of reduced risk of total  
mortality or cardiovascular events in patients treated with omega-3 fatty acids (94). 
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1.5.5 Other lipid-lowering medications 
Resins bind bile acids in the intestine, thereby interrupting the enterohepatic 
circulation of bile acids. The conversion of cholesterol into bile acids in the liver is 
therefore increased in addition to the hepatic synthesis of cholesterol. This results in 
increased secretion of VLDL into the circulation and consequently raised plasma TG 
levels (86). In contrary, ezetimibe is thought to inhibit a cholesterol transporter in the 
enterocytes, located within the brush-border membrane of the small intestine. 
Ezetimibe has been shown to reduce the LDL-cholesterol and TG levels, in addition 
to cause a modest increase in HDL-cholesterol (95). 
Table 5 .The effects of different medications on lipoprotein levels (96). 
 Total-
cholesterol 
LDL-
cholesterol 
HDL-
cholesterol 
TG 
Statin ↓ 15-60 % ↓ 20-60 % ↑ 3-15 % ↓ 10-40 % 
Fibrate ↓ 15 % ↓ 0-15 % ↑ 6-15 % ↓ 20-50 % 
Niacin ↓ 25 % ↓ 10-15 % ↑ 15-35 % ↓ 20-50 % 
Fish oil ↑ or neutral ↑ or neutral ↑ or neutral ↓ 20-50 % 
Ezetimibe ↓ 12 % ↓ 18 % ↑ 1 % ↓ 8 % 
 
 
1.6 Therapeutic lifestyle changes 
Patients with elevated TG levels may benefit from therapeutic lifestyle changes, 
including change of diet, weight reduction and increased physical activity (6).  
1.6.1 Diet 
The National Cholesterol Education Program recommends a dietary approach to 
reduce the overall risk of CHD. Its essential features are a carbohydrate intake 
representing 50-60 % of total calories, 20-30 g fibre daily, and total fat contributing 
with 25-35 % of total calories, with reduced intake of saturated fats (<7 % of total 
calories), and cholesterol (<200 mg/d) (6). At the Lipid Clinic, Oslo University 
Hospital-Rikshospitalet they have the following dietary guidelines for patients with 
hyperlipidemia: total fat intake contributing with 25 % of total calories, where 
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saturated fat and trans-fatty acids should be restricted to <7 % and <1 % of total 
calories respectively. The intake of monounsaturated fatty acids should represent 10-
15 % and polyunsaturated fatty acids 5-10 % (included 1 % from omega-3 fatty 
acids) of the total calorie intake. The intake of cholesterol should be restricted to 
<200 mg per day. Protein intake should contribute with 10-20 % of total calories, and 
carbohydrates 50-60 % of total calories, where maximum 10 % should originate from 
sugar. In addition, they recommend an intake of 25-35 g fibre, and 2 g plant sterols 
per day. To achieve these goals the patients referred to the Lipid Clinic will be 
recommended to eat less fat, and to use plant- and fish-fat as a main source in stead of 
animal-fat, thus replacing some saturated fat with unsaturated fat in the diet. The 
patients are also recommended to eat more food rich in fibre, for instance fruit and 
vegetables, and to eat less of the cholesterol-rich food. Patients who are overweight 
and/or have elevated TG levels are also recommended to reduce their intake of 
alcohol and sugary food and drinks (more diet recommendations can be found in 
appendix 4) (97). 
1.6.2 Physical activity 
Increased exercise is one of the cornerstones of TG-lowering therapy (6). Aerobic 
exercise has shown to significantly reduce postprandial lipemia, and significantly 
increase LPL activity (98). The lipemic response to a meal high in fat and 
carbohydrate is also related to the intensity of the preceding exercise. In one study, 
the fasting and postprandial TG concentration was significantly lower after moderate 
intensity walking compared with the controls. However, the TG concentration was 
not significantly lower after low intensity walking (99).  
1.6.3 Smoking 
Axelsen et al found that habitual smokers had a 50 % higher postprandial increase in 
TG levels than non-smokers (100). However the fasting TG levels were the same in 
both groups. A different study showed that smokers had a significantly increased 
postprandial TG response in chylomicrons. In addition, smoking raised apo B-48 
postprandially, but apo B-100 concentrations and lipolytic enzymes were similar in 
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the smoking and in the non-smoking group (101). This might indicate that smoking 
can lead to a postprandially increase in lipoproteins of intestinal origin. Cessation of 
smoking will therefore be beneficial in patients with hypertriglyceridemia. 
1.7 Cardiovascular disease 
Cardiovascular disease (CVD) is a group of disorders that affects the heart and blood 
vessels. These conditions include CHD, cerebrovascular disease (cerebral infarction, 
cerebral bleeding), peripheral arterial disease, rheumatic heart disease, congenital 
heart disease, deep vein thrombosis and pulmonary embolism. CVD is the number 
one cause of death globally. It is estimated that 17.5 million people died from CVD in 
2005, representing 30 % of all global deaths (102). 
1.7.1 Vascular risk factors in general 
Age, sex, personal and family history of CVD are non-modifiable risk factors for 
CHD (103). Modifiable factors like unhealthy diet, physical inactivity and tobacco, 
are responsible for about 80 % of CHD and cerebrovascular disease. The effects of an 
unhealthy diet and physical inactivity may be raised blood lipids, blood glucose, 
blood pressure, overweight and obesity (102). For high risk individuals the goal 
regarding blood lipids is: total-cholesterol <5 mmol/L and LDL-cholesterol <3 
mmol/L, while HDL-cholesterol <1 mmol/L and fasting TG >2.0 mmol/L are 
markers of increased CHD risk (104) . 
1.7.2 Elevated triglycerides as a risk factor 
Elevated cholesterol levels, in addition to low HDL-cholesterol levels, are regarded 
as important risk factors for CHD (103). Several studies are now indicating that 
elevated TG levels might also constitute a significant, independent risk for CVD in 
men and women in the general population (105). Pelkonen et al found that the 
relation between  TG concentration and cardiovascular death was not linear (106). 
Increased risk were only seen when TG concentration was >1.7 mmol/L. This 
discovery makes TG different from other risk variables, like plasma cholesterol 
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concentration, cigarette smoking and blood pressure which are linearly correlated 
with disease events. In comparison, the Copenhagen Male Study concluded that the 
risk of CHD increased with TG levels above 1.1 mmol/L (107). This study followed 
2906 men, who were initially free of overt CVD, for eight years. The study 
population was divided into thirds (three groups) based on their TG level: <1.1 
mmol/L, 1.1-1.6 mmol/L and >1.6 mmol/L. They found a clear gradient of risk for 
CHD with increasing thirds of TG levels. Compared with the lowest third, the risk of 
CHD was 50 % higher in the middle third and 120 % higher in the highest third after 
controlling for other major risk factors.  
In the Prospective Cardiovascular Munster Study (PROCAM) they analyzed 
cardiovascular risk factors in nearly 5000 male participants aged 40-65 years in a 
follow-up period for 8 years (108). Analyses revealed that moderately elevated levels 
of TG emerged as an independent predictor for the risk of major coronary events 
(nonfatal myocardial infarction, fatal myocardial infarction, sudden cardiac death). 
The ranking of the continuous risk factors for predictive value for CHD was: LDL-
cholesterol > total-cholesterol > HDL-cholesterol > TG > fasting blood glucose > 
systolic blood pressure > body mass index.  
Blood lipid alterations after a fatty meal may be atherogenic. The Atherosclerosis 
Risk in Communities Study showed an association between postprandial TG and 
carotid atherosclerosis defined by intima-media thickness. This finding was 
independent of fasting lipids and other risk factors in non-obese, white, middle-aged 
subjects (109). An elevated level of non-fasting TG is a marker for elevated levels of 
CM and VLDL remnant particles which are able to promote atherosclerosis. These 
remnant lipoproteins can penetrate into the arterial intima, and get trapped within the 
subendothelial space (110). Several recent studies have focused on non-fasting TG 
levels and risk of myocardial infarction. The Copenhagen City Heart Study is a 
prospective cohort study which included 13956 participants (111). They found that 
the cumulative incidence of ischemic stroke increased with increasing levels of non-
fasting TG. The significant results showed that the hazard ratios for ischemic stroke 
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in men with non-fasting TG of 3.99-4.98 mmol/L and >4.98 mmol/L were 2.2 and 2.5 
respectively, compared to men with non-fasting levels less than 1 mmol/L.  
It is not known whether the relation between TG and CHD is primarily direct or 
indirect. TG-rich lipoproteins, particularly VLDL, may be directly atherogenic, or the 
hypertriglyceridemia may lead to metabolic consequences which contribute to CVD.  
These consequences might be an increase in postprandial lipoproteins, large VLDL 
particles, small and dense LDL particles, a low level of HDL-cholesterol and/or 
possibly a procoagulant state (112). Not all VLDL particles are atherogenic. It is the 
elevation of small cholesterol rich VLDL particles that are associated with an 
increased risk of CHD, while the increase in large TG-enriched VLDL particles is not 
associated with increased CHD risk (113). In addition, hypertriglyceridemia may 
enhance thrombogenesis through abnormal alterations in coagulation and fibrinolytic 
mechanisms (114). It has been reported that higher plasma fibrinogen concentrations 
and higher factor VII coagulant activity are associated with greater risk of 
cardiovascular disease (115). The fibrinolytic system is regulated by the balance 
between the levels of tissue-plasminogen activator (t-PA) and plasminogen activator 
inhibitor (PAI-1). In one study they found that the plasma levels of both t-PA and 
PAI-1 were significantly higher in patients with hypertriglyceridemia than in 
normolipidemic patients, and that PAI-1 levels tend towards normalization in 
conjunction with TG reduction (114). Others have reported alterations in fibrinolytic 
activity in patients with hypertriglyceridemia. A study by Hamsten et al showed that 
the level of t-PAI was positively and significantly correlated with levels of serum TG 
(116). This study included 71 persons who had suffered a myocardial infarction, and 
these patients were compared with 50 healthy persons three years after the infarction. 
They found a low t-PA activity after venous occlusion in the patients, explained by 
high plasma levels of t-PAI and to some extent impaired release of t-PA from the 
vessel wall. This data implied that reduced fibrinolytic capacity, due to increased 
plasma levels of t-PAI, may have a pathogenic importance in myocardial infarction, 
particularly in patients with hypertriglyceridemia. In addition, another study where 
they analyzed data from The Atherosclerosis Risk in Communities Study, showed 
 43
that plasma TG, LDL-cholesterol, HDL-cholesterol and BMI are positively 
associated with coagulation factor VII (115). In this study, TG showed the most 
striking correlation: a 0.8 mmol/L increase in TG concentration resulted in a nearly 
10 % increase in factor VII.  
1.8 Acute pancreatitis 
Acute pancreatitis is a relatively common disorder with increasing incidence and 
several possible etiologies. The clinically appearance can vary from mild self-limiting 
symptoms to a deadly disease (117). 
1.8.1 Pathophysiology of acute pancreatitis 
Acute pancreatitis is probably caused by an unregulated activation of trypsin within 
the pancreatic acinar cells. This enzyme activation will lead to an autodigestion of the 
gland and local inflammation. Acute pancreatitis can arise when intracellular 
protective mechanisms, which shall prevent trypsinogen activation and reduce trypsin 
activity, are overwhelmed. Examples of such protective mechanisms include the 
synthesis of trypsin as the inactive enzyme trypsinogen, autolysis of activated trypsin, 
enzyme compartmentalisation and synthesis of specific trypsin inhibitors. After 
activation of trypsinogen to trypsin within the acinar cells other enzymes are also 
activated, for instance elastase and phospholipase A2. Activation of these digestive 
enzymes leads to pancreatic injury and results in an inflammatory response. This 
acute inflammatory response itself causes substantial tissue damage (117). 
1.8.2 Etiology and epidemiology 
The most important risk factors for pancreatitis in adults are gallstone and excessive 
alcohol use. Other causes of acute pancreatitis are metabolic aberrations, like 
hypertriglyceridemia, duct obstruction, medications and trauma (118). In a 
Norwegian study of 376 patients, they found that gallstone was the cause in 58 % of 
the episodes with acute pancreatitis, alcohol in 13 %, hyperlipidemia in 2.4 %, and 14 
% of the cases were idiopathic (119). Another study have found that severe 
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hypertriglyceridemia was the cause in 7 % of the episodes of acute pancreatitis (120). 
Hypertriglyceridemia as the causative factor in acute pancreatitis differs between 
studies, thus indicating that hypertriglyceridemia can be difficult to detect and 
diagnose as the real causative factor. This might in some cases lead to an 
underestimation of hyperlipidemic pancreatitis.  
The incidence of acute pancreatitis seems to be increasing in European countries, and 
the incidence and mortality rate are also increasing with age. Differences in both the 
incidence and the etiology of acute pancreatitis exist between countries (121). It is 
estimated that 10 to 30 % of those with severe acute pancreatitis will most likely die 
(118). 
1.8.3 Diagnosis of acute pancreatitis 
Acute pancreatitis is characterized by the presence of acute and constant pain in the 
epigastric area. This pain might be associated with nausea and vomiting. Elevated 
amylase and/or lipase are the diagnostic hallmarks of acute pancreatitis. Amylase 
concentrations normally rise in the serum within a few hours after onset of symptoms, 
and return to normal values within 3-5 days (117). In the case of pancreatitis due to 
hypertriglyceridemia, serum and urinary amylase levels are low and may also be 
normal in more than 50 % of the patients at the time of admission or at the hospital 
stay (122). This has been explained by the presence of an inhibitor in the plasma and 
urine that inhibits the assay (123). 
The strongest predictor of hyperlipidemia in a patient with acute pancreatitis is the 
presence of lipemic plasma. Within 24-48 hours of the onset of acute pancreatitis, TG 
levels usually fall rapidly as a consequence of fasting. In addition, the therapy with 
hypocaloric intravenous fluids leads to a decrease in the secretion of VLDL from the 
liver (122). The plasma TG level might be only slightly elevated or even normal a 
few days after hospital admission. Therefore it is important to consider 
chylomicronemia at the time of admission to make a correct conclusion about 
etiology (120). In addition, family history or preexisting medical conditions and 
medications known to cause hypertriglyceridemia can contribute to identification of 
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patients with hypertriglyceridemia-induced pancreatitis (122). Computed 
Tomography can be done to confirm the diagnosis (117). 
1.8.4 Hypertriglyceridemia and acute pancreatitis 
Patients with hypertriglyceridemia and pancreatitis usually have a preexisting 
abnormality in lipoprotein metabolism (122). A plasma TG level >11 mmol/L has 
shown to be associated with an increased risk of acute pancreatitis in patients with 
type I, IV or V hyperlipoproteinemia, with an incidence of acute pancreatitis up to 21 
% (124). An elevation in TG level (2-10 mmol/L) is common in early phase of acute 
pancreatitis of any etiology. However, this elevation is more likely to be an 
epiphenomenon of the pancreatic disease rather than a true causal precipitant. A 
much more marked hypertriglyceridemia would be needed to trigger an acute 
pancreatitis (125).  
1.8.5 Pathogenesis of hypertriglyceride-induced pancratitis 
In TG-induced pancreatitis there are elevated levels of CM particles in the 
circulation, and these particles are believed to be responsible for the pancreatic 
inflammation. These large lipoproteins might impair circulatory flow in the capillary 
beds. This can lead to ischemia in the pancreas and hence disturbs the acinar structure 
and expose the TG-rich lipoproteins to pancreatic lipase. Hydrolysis of TG in and 
around the pancreas leads to accumulation of free fatty acids in high concentrations. 
Unbound free fatty acids are toxic and can produce acinar cell or capillary injury, in 
addition to activate trypsinogen and with that initiate acute pancreatitis. 
Subsequently, there will be a release of inflammatory mediators and free radicals and 
the result might be necrosis, edema and inflammation (122). An animal study which 
examined the development of pancreatitis due to hyperlipoproteinemia type 1, found 
that mitochondrial swelling was the dominating early change in the pancreas. Fatty 
acids are known to induce mitochondrial swelling, and increased concentrations of 
free fatty acids in the acinar cells might therefore trigger reactions that lead to 
pancreatitis (126). The inflammatory response may progress beyond the pancreas to a 
systemic inflammatory response syndrome, multiorgan failure or death (117).  
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1.9 Current issues 
This is the first study to examine the occurrence of conditions associated with severe 
hypertriglyceridemia in Norway. Since the Norwegian population might differ from 
those in other countries with respect to occurrence of conditions associated with 
hypertriglyceridemia, this knowledge is of clinically importance. The characterization 
of patients with severe hypertriglyceridemia is important since it can enable clinicians 
to identify patients at risk. In addition, hypertriglyceridemia as a result of secondary 
conditions might be overlooked and remained untreated. Therefore, it is of clinical 
significance that conditions which are usually associated with high TG values are 
well known, so patients can receive an adequate treatment, and achieve a reduced risk 
of CHD and pancreatitis. 
The Lipid Clinic is an out-patient`s clinic at Oslo University Hospital-Rikshospitalet, 
which receives referrals of patients from all over the country. The clinic gets 
approximately 700 new-referrals each year, and has an important role in the treatment 
of patients with hyperlipidemias from all over Norway. It is of interest and 
importance to evaluate the effect of the treatment at the Lipid Clinic, with reference 
to clinical measures and blood lipids. Such an evaluation might contribute to better 
treatment of patients with hypertriglyceridemia in the future. 
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2. Aims and approach to the problems 
The following questions will be answered: 
(i) What are the most common primary and secondary causes of severe 
hypertriglyceridemia in patients receiving treatment at the Lipid Clinic, 
Oslo University Hospital-Rikshospitalet? 
(ii) What kind of treatment have these patients received at the Lipid Clinic? 
(iii) How can this population be described with regard to clinical 
measurements and blood samples before start of treatment at the Lipid 
Clinic? What alterations have occurred in these clinical parameters and 
in their blood lipids after treatment at the Lipid Clinic? 
(iv) How common is the presence of pancreatitis and CHD in this 
population? 
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3. Study design, study population and method 
3.1 Study design 
In the present study, already existing data was collected from medical records to the 
participants. The study was a retrospective and descriptive study. 
3.2 Approvals 
The study protocol was approved by the Regional Committee for Medical Research 
Ethics (appendix 1), in addition to the Data Inspectorate (appendix 2). 
3.3 Study population 
The study included individuals who were referred to the Lipid Clinic, Oslo University 
Hospital-Rikshospitalet, in the period 2002-2007. The patients were identified by 
searching the medical records for patients with the hypertriglyceridemia diagnoses 
(ICD-10 classification): pure hypertriglyceridemia (E78.1), mixed hyperlipidemia 
(E78.2) and hyperchylomicronemia (E78.3). To be included in the study the patients 
had to have a measured fasting TG level ≥10 mmol/L at some point during their 
treatment at the Lipid Clinic. The patients had to be 18 years or older.  
In total, 112 patients from all over Norway fulfilled the inclusion criteria. These 
persons received a letter with information about the aim and form of the study, along 
with a consent form they were asked to sign and return if they agreed to participate in 
the study (appendix 3). Those who did not respond to the first information letter 
received the same letter once more. Finally, those who had not responded to neither 
of the letters were called and informed verbally about the study, and the importance 
of their participation. In total, 65 persons returned their written informed consent, and 
agreed to participate in the study (figure 4). 
 49
 
112 patients fulfilled the inclusion criteria.
28 persons returned a written consent, and 
agreed to participate in the study. 
20 persons returned a written consent, and 
agreed to participate in the study. 
17 persons returned their signed consent 
after the phone call.
Information letters were sent 
out for the second time to the 79 
persons who had not responded. 
1 person responded negative. 
1 person had died. 
3 letters came in return 
because of unknown address. 
7 persons said they would return 
their consent, but never did. 
20 persons responded that they 
did not want to participate. 
14 persons were not reachable on 
the phone. 
1 person returned the consent 
form, but was not included 
because of late response. 
The remaining 59 persons 
who still had not answered 
were called, and informed 
about the study. 
65 persons in total gave their signed
consent to participate in the study.
Information letters were 
sent out by mail to the 
112 patients. 
 
Figure 4. Flowchart showing the inclusion process of the participants. 
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3.4 Methods 
3.4.1 Data collection 
The medical records of the participants were used as a source for information in the 
present study. Data on age, diagnoses, clinical measures, blood samples, medications 
and lifestyle were collected from these records, and registered in an excel file. The 
data was de-identified by aid of identity numbers.   
3.4.2 Visits to the Lipid Clinic 
The included participants had their first visit to the Lipid Clinic at some point in the 
period 2002-2007. However, the number of visits, in addition to the period between 
each visit, was highly variable for the participants. Five of the patients had no 
registered follow-up at the Lipid Clinic after their consultation in this period. 
However, the median time of registered follow-up consultations was 2 years and 2 
months.  
3.4.3 Diagnoses 
All the diagnoses which were recorded in the medical records were registered in the 
present study. Therefore, which diagnoses that were to be included were not 
determined at the start of the study, but rather during reading the medical records. 
Since several patients had more than one diagnosis, some of the patients have been 
recorded under several of the diagnoses. In the present study, the hyperlipidemias in 
the Fredrickson system were defined as primary diagnoses, while the other diagnoses 
were defined as secondary diagnoses. 
All the diagnoses were made by a doctor, either before the patient came to the Lipid 
Clinic, or during the time there. One exception was the metabolic syndrome, which 
was diagnosed during this study in the patients that fulfilled the criteria for the 
diagnosis. Several definitions of the metabolic syndrome exist. Table 6 compares two 
of the customary definitions. The definition from the International Diabetes 
Federation requires an increased waist circumference in addition to at least two other 
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risk factors (127). In comparison, the definition from the National Cholesterol 
Education Program does not require an increased waist circumference, but states that 
all risk factors are equally important. According to this definition, ≥3 risk factors 
must be present in the patient (6). The definition from the National Cholesterol 
Education Program was used in the present study. 
Table 6. Two commonly used definitions on the metabolic syndrome. 
The National Cholesterol Education  
Program 
The International Diabetes Federation 
≥3 of the following risk 
factors: 
Limit values: Increased waist circumference 
+ ≥2 other risk factors: 
Limit values: 
Waist circumference (cm) 
-men 
-women 
 
>102 
>88 
Waist circumference (cm) 
-men 
-women 
 
≥94 
≥80 
TG (mmol/L) ≥1.7 TG (mmol/L) >1.7 
HDL-cholesterol (mmol/L) 
-men 
-women 
 
<1.03 
<1.29 
HDL-cholesterol (mmol/L) 
-men 
-women 
 
<0.9 
<1.1 
BP1 (mmHg) ≥130/≥85 BP1 (mmHg) ≥130/≥85 
Fasting glucose2 (mmol/L) ≥5.6 Fasting glucose2 (mmol/L) ≥5.6 
1 The criteria is also fulfilled if the patient is treated medically for hypertension 
2 The criteria is also fulfilled if the patient has type 2 diabetes 
 
Participants registered with pancreatitis in the present study included patients who 
had experienced pancreatitis before the start of treatment at the Lipid Clinic and/or 
during their time there. Similar, the category denoted CHD included both participants 
diagnosed with CHD before they came to the Lipid Clinic, in addition to participants 
who were diagnosed with CHD during their treatment there. CHD includes four 
different syndromes: (1) angina pectoris, (2) acute myocardial infarction, (3) sudden 
cardiac death, and (4) chronic ischemic heart disease with congestive heart failure 
(128).  
Patients registered as having reumatic disease included participants with Bechterevs 
disease, arthritis, rheumatic arthritis and gout. The disease category denoted kidney 
disease, included patients with kidney failure and nephritis, while patients diagnosed 
with lung disease had either chronic obstructive pulmonary disease or asthma. 
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3.4.4 Medication 
Information about type and doses of medications were collected from the medical 
records. Only lipid-lowering medications were registered, in addition to some other 
medications known to have an effect on the lipid profile, like anti-diabetic 
medications, xenical and antihypertensive medications. 
3.4.5 The SmartDiet questionnaire 
Lifestyle advice and recommendations for changes are an important part of the 
treatment at the Lipid Clinic. SmartDiet is a questionnaire with 25 questions about 
diet and lifestyle (appendix 4). All patients referred to the Lipid Clinic will fill out 
this questionnaire before each consultation. Based on the answers, the patients will 
receive recommendations with respect to lifestyle changes which can improve their 
lipid profile and health. The SmartDiet questionnaire is not available in the medical 
records to the patients, and information regarding the total score on this questionnaire 
was obtained from notes in the medical records made by the nutritionist or the doctor 
in the present study. Alterations in some of the measured lifestyle parameters were 
interpreted as possibly results of adherence to the recommendations they received at 
the Lipid Clinic. 
It is possible to score 1 to 3 points on each question regarding the diet, where 1 equals 
a bad score and 3 a good score. The total sum of the scores is an estimation of the 
dietary habits to the individual (129). Based on these scores the doctor or nutritionist 
can give advice to the patients regarding how they can improve their diet. 
The SmartDiet form was revised in 2007. The participants in the present study have 
therefore either used the oldest, newest, or both editions. However, both editions 
divide the total evaluation of the diet into three categories. The lowest score give the 
following characterisation of the diet: “You should improve your diet in several 
ways, to make it more heart-friendly”, a medium total score: “You can improve your 
diet, to make it more health- and heart friendly” and a high total score: “You have a 
healthy diet”. In this study each of these categories were denoted a score from 1 to 3 
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respectively. Change in total score from start to end of treatment was estimated and 
divided into following categories: the score was the same, worse or improved. 
The category regarding alcohol intake have the following division in the SmartDiet 
questionnaire: no, little (<1 unit per week), moderate (1-7 units per week), high (8-14 
units per week) and very high (>15 units per week). One unit is defined as 125 ml 
wine or 0.33 l beer or 4 cl spirits. Each category was in the present study given a 
score from 0 to 4 respectively. To investigate the mean alcohol intake, all the reported 
scores on alcohol intake were added and then divided on the total number of scores 
registered for each patient. Regarding smoking habits, the different categories are: no, 
party smoker and smoking at a daily basis. Degree of physical activity is divided into: 
0-1 time per week, 1-2 times per week and ≥3 times per week. One time is defined as 
physical performance for at least 30 minutes, for instance swimming, running, skiing 
or bicycling. 
Not all the participants had answered the SmartDiet questionnaire. The information 
regarding diet and lifestyle was therefore incomplete for many of the patients. 
3.4.6 Clinical measurements 
Height, weight, waist circumference and blood pressure (BP) were identified in the 
medical records. By aid of this information, it was possible to estimate the Body mass 
index (BMI) for each participant. BMI is an index of weight-for-height that is 
commonly used to classify underweight, overweight and obesity in adults. BMI is 
defined as weight in kilograms divided by the square of the height in metres (kg/m2). 
WHO defines BMI <18.5 kg/m2 as underweight, BMI 18.5-24.9 kg/m2 as normal 
weight, BMI  25.0-29.9 kg/m2 as overweight and BMI >30 kg/m2 as obesity (130). 
Some of the participants had never taken these measurements, while others had taken 
them several times. As a consequence, the information about many of these 
parameters was incomplete. 
Time intervals were defined to decide which measurements were to be included, and 
to make it possible to estimate the change in these parameters following baseline 
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(table 7). The baseline values refer to the measurements taken at the first visit to the 
Lipid Clinic. To ensure that as much data as possible would be included in the 
analyses, results from measurements taken after 0.5, 1, 2 and 3 years following 
baseline were selected. However, since the time between the measures was highly 
variable, clinical measurements taken 3 months before/after these specified times 
were also included. For those participants with only one registered measure, it was 
not possible to calculate the change after a treatment period. After plotting all the 
clinical measurements for each patient on each time interval, it became clear that only 
a small number of participants had a registered waist circumference following 
baseline. Therefore, the alterations following baseline were only estimated for weight 
and blood pressure. 
Table 7. Time intervals for included clinical findings and blood parameters. 
 Time intervals 
Baseline At the start of treatment 
0.5 years  6 months ± 3 months after baseline 
1 year  1 year ± 3 months after baseline 
2 years  2 years ± 3 months after baseline 
3 years 3 years ± 3 months after baseline 
  
3.4.7 Blood samples 
Nineteen different blood parameters of interest were collected from the medical 
records of the patients and used in the study. The parameters were the following: 
glucose,  HbA1c, serum-insulin, c-peptide, total-cholesterol, LDL-cholesterol, HDL-
cholesterol, TG, lipoprotein little a (Lp (a)), apo A1, apo B, c-reactive protein (CRP), 
thyroidea-stimulating hormone (TSH), free thyroxin (FT4), aspartate 
aminotransferase (ASAT), alanine aminotransferase (ALAT), creatinine kinase (CK), 
creatinine and pancreas amylase. These blood parameters were taken after at least 12 
hours fasting, and were analyzed at Oslo University Hospital-Rikshospitalet. 
Laboratory results which were reported as Lp (a) values <100 mg/L and CRP values 
<10 mg/L were not included since these results were to unspecified. 
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Not all the participants had measured these 19 blood parameters. In addition, some of 
them had only taken one blood sample, while others had taken several. The time 
intervals which decided which blood samples were to be included in the study were 
the same as for the clinical measurements (table 7). In addition to values measured in 
these time intervals, the referral values for TG levels were also included in some 
analyses. These values represent those who were reported in the referral letters, which 
were sent to the Lipid Clinic by the general practitioners of the patients. Results from 
the blood samples were registered in an excel file with a column for each parameter 
measured at different times, and a row for each individual. 
3.4.8 Triglyceride quartiles 
Since the TG values taken at the first visit at the Lipid Clinic showed a wide 
distribution, the participants were divided into quartiles according to their first 
measured TG values, so these four groups could be compared with respect to clinical 
findings and secondary diagnoses, and to make it possible to determine if those with 
the highest TG values at the start of treatment differed from the rest of the patients. 
The patients were divided into the following groups: (1) patients with TG ≤10 
mmol/L, (2) patients with TG >10 mmol/L and ≤20 mmol/L, (3) patients with TG 
>20 mmol/L and ≤30 mmol/L, and (4) patients with TG >30 mmol/L. 
3.4.9 Statistics 
All statistical analyses were performed with SPSS (Statistical Package for the Social 
Sciences) version 16.0. First the data were checked to decide whether they fulfilled 
the criteria for a normal distribution. This was done by the Shapiro- Wilks normality 
test, and evaluation of histograms and Q-Q-plots. Most of the data did not show a 
normal distribution, and non-parametric statistical analyses were therefore mainly 
used. Results from non-parametric statistical analyses are reported as median and 95 
% confidence interval (95 % CI) to the median. Results from variables that showed a 
normal distribution are reported as mean and standard deviation (SD) of the mean. P-
values less than 0.05 were considered as statistically significant. Wilcoxon Signed 
Rank Test and Paired-Samples T-Test were used to evaluate the change in clinical 
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measures and blood parameters. Chi-square test for independence and Mann-Whitney 
U Test were used to detect possible differences in patients with and without CHD and 
pancreatitis. McNemar`s test was used to evaluate possible alterations in the use of 
medications and in lifestyle parameters following baseline. Kruskal-Wallis Test was 
used to compare clinical findings in patients divided into groups according to their 
TG values (TG quartiles). Logistic regression was used to determine how well 
different variables could explain the presence of CHD in the present study. 
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4. Results 
Sixty-five out of the 112 patients (58 %) that fulfilled the inclusion criteria agreed to 
participate in the present study. Among the participants, 51 were men and 14 were 
women. The mean age was 45.8 years. 
4.1 Diagnoses 
All the participants had either a primary diagnosis, one or several secondary 
diagnoses or combinations of both primary and secondary diagnoses registered in 
their medical records, except for one patient. 
4.1.1 Primary hypertriglyceridemia 
Among the participants, only 28 patients had a registered primary diagnosis that 
could explain their hyperlipidemia. These diagnoses were based on genetic findings 
and/or clinical and familial characteristics typical for primary hyperlipidemias (table 
8). Familial combined hyperlipidemia was the primary diagnosis with highest 
occurrence in the present study, and was diagnosed in 17 patients (26 %). Gene tests 
and available information about familial disposition could, however, not explain the 
hyperlipidemia in the rest of the patients. Among those without a confirmed primary 
cause of their hypertriglyceridemia, 19 participants were referred to the Lipid Clinic 
based on combined hyperlipidemia, and 18 participants for hypertriglyceridemia. 
However, 2 of these patients possibly had a primary mixed hyperlipidemia (type V), 
but this diagnosis was not completely confirmed. 
All of those with a primary cause of their hyperlipidemia had one or several 
secondary diagnoses in addition, with the exception of one person diagnosed with 
primary mixed hyperlipidemia. There were no significant differences in the presence 
of various secondary diagnoses between the groups of primary diagnoses. Table 9 
contains information about the occurrence of the most common secondary conditions 
seen in patients with a primary diagnosis. 
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Table 8. Number of patients with primary hyperlipidemias. 
 Dyslipidemia Fredricksons classification ICD-10 n 
Familial chylomicronemia Type I E78.3 0 
Familial hypercholesterolemia Type IIa E78.0 0 
Familial combined hyperlipidemia Type IIb E78.4 17 
Familial dysbetalipoproteinemia Type III E78.2 3 
Familial hypertriglyceridemia Type IV E78.1 2 
Primary mixed hyperlipidemia Type V E78.3 6 
Total   28 
 
Table 9. Secondary diagnoses in combination with primary hyperlipidemias. 
Fredricksons 
classification 
Type IIb 
n=17 
Type III 
n=3 
Type IV 
n=2 
Type V 
n=6 
Secondary diagnoses % n % n % n % n 
Metabolic syndrome 83 15 67 2 100 2 83 5 
Hypertension 50 9 33 1 0 0 50 3 
CHD 39 7 33 1 0 0 33 2 
Type 2 diabetes 22 4 33 1 50 1 50 3 
Reumatic disease 39 7 33 1 0 0 17 1 
Pancreatitis 17 3 0 0 0 0 50 3 
Hypothyroidism 11 2 33 1 50 1 17 1 
 
 
 
4.1.2 Secondary hypertriglyceridemia 
Thirty-seven participants had no primary diagnosis recorded in their medical records. 
However, nearly all had one or several secondary conditions in addition to their 
hyperlipidemia. Thus, their hyperlipidemia might therefore be a result of the presence 
of these conditions (secondary hyperlipidemia). Considering the whole study 
population, over 60 % had ≥3 secondary diagnoses recorded in their medical records 
(table 10). One of the patients without a secondary diagnosis had a registered primary 
cause that could explain the hyperlipidemia, namely a primary mixed 
hyperlipoproteinemia. Only one patient had no registered primary or secondary 
conditions. The metabolic syndrome, hypertension and type 2 diabetes were the 
diagnoses most frequently seen in this group of patients (figure 5). 
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Table 10. Number of patients with no /several secondary diagnoses. 
Number of secondary diagnoses Number of patients 
 n % 
0 2 3.1 
1 11 16.9 
2 11 16.9 
≥3 41 63.1 
Total 65 100 
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Figure 5. Number of patients with different secondary diagnoses, n=65. 
1 Includes patients with established CHD before they came to the Lipid Clinic and patients who were 
diagnosed with CHD during the time they were patients at the Lipid Clinic.   
2 Four of the 12 patients with reumatic disease had arthritis urica. 
3 MELAS, Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes.   
4.2 Treatment of hypertriglyceridemia 
All the participants used one or several medications in their treatment at the Lipid 
Clinic, except for 4 patients. However, they all received advice and recommendations 
regarding a healthy lifestyle and diet, either in group or at individual consultations 
with a nutritionist. 
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4.2.1 Medications 
Half of the study population (n=33) used one or several lipid-lowering medications 
when they first came to the Lipid Clinic. However, this group of patients did not 
include all of those with the highest reported TG concentration in the referral letters. 
For instance, no medication therapy was initiated for a patient with reported TG 
concentration of 62.5 mmol/L. Among those who already used medications, statins 
were the most commonly used medication group, where atorvastatin was the type 
most utilized. As many as 28 patients reported intake of different fish oil 
preparations, where 11 of these used the concentrated omega-3 preparation, Omacor, 
in different doses. Several patients also used medications in combination. Statins 
were included in all these combinations, and were used together with either Omacor 
(n=6), resins (n=1) or Omacor in addition to a fibrate (n=1). 
At the last consultation, 89 % of the participants used one or several lipid-lowering 
medications. This represents a significant increase in the number of patients who 
started on lipid-lowering medications after they came to the Lipid Clinic (p <0.001). 
There was an increase in the use of statins, as well as fibrates. However, the greatest 
change was in the use of Omacor. Thirty-one more patients used this medication at 
their last consultation compared to baseline. In addition, the majority used several 
medications in combination (table 11). Only 7 patients used statins alone, 2 patients 
used fibrates alone and 6 patients used Omacor alone. The remainder used up to four 
preparations simultaneously. Table 12 contains information about type and doses of 
lipid-lowering medications which were used at the start and end of treatment at the 
Lipid Clinic. 
In total, 53 participants used statins at some point during their treatment at the Lipid 
Clinic, 46 participants used Omacor, 30 participants used fibrates, and 11 participants 
used other lipid-lowering medications (ezetimibe, nicotinic acid, resins). Four 
patients did not use any lipid-lowering medications at all. 
Some patients used other medications in addition to the lipid-lowering types, for 
instance Xenical (n=5), thyroxine (n=9) and antidiabetica (n=20). Regarding 
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medications which might contribute to elevated TG levels, 24 patients used 
antihypertensive medications when they came to the Lipid Clinic, and 35 patients in 
total used antihypertensive medications during their treatment at the Lipid Clinic. In 
addition, one patient used resins at the start of treatment at the Lipid Clinic, while 5 
patients in total used resins at some point during their treatment at the Lipid Clinic. 
All the patients who used resins in their treatment used other lipid-lowering 
medications in addition. 
 
Table 11. Combinations of medications used at the end of treatment, n=43. 
Combinations n 
Statin + Omacor 16 
Statin + Fibrate 4 
Fibrate + Omacor 3 
Statin + Ezetimibe 1 
Statin + Omacor + Fibrate 11 
Statin + Omacor + Ezetimibe 2 
Omacor + Ezetimibe + Resin 1 
Statin + Fibrate + Ezetimibe 1 
Statin + Ezetimibe + Nicotinic acid 1 
Nicotinic acid + Omacor + Ezetimibe 1 
Statin + Omacor + Fibrate + Ezetimibe 2 
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Table 12. Medications used at the Lipid Clinic, n=65. 
 
Type and dose At the start of 
treatment, n=33 
At the end of 
treatment, n=58 
 % n % n 
Statins: 
Atorvastatin:   10 mg 
                        20 mg 
                        40 mg 
                        60 mg 
                        80 mg 
Simvastatin:    20 mg 
                        40 mg 
                        80 mg 
                       120 mg 
Fluvastatin:     20 mg 
                        40 mg 
Pravastatin:     20 mg 
                        40 mg 
                        80 mg 
Unknown  
44.6 
0 
0 
24.1 
6.9 
20.7 
6.9 
6.9 
10.3 
3.5 
0 
3.5 
3.5 
6.9 
3.5 
3.5 
29 
0 
0 
7 
2 
6 
2 
2 
3 
1 
0 
1 
1 
2 
1 
1 
69.2 
4.4 
13.3 
24.4 
0 
20.0 
6.7 
22.2 
0 
0 
2.2 
0 
0 
4.4 
0 
2.2 
45 
2 
6 
11 
0 
9 
3 
10 
0 
0 
1 
0 
0 
2 
0 
1 
Fibrates: 
Bezafibrate:     200 mg 
                        400 mg 
                      4200 mg 
Fenofibrate:    160 mg 
                        200 mg 
                        300 mg 
1.5 
0 
0 
0 
0 
0 
100.0 
1 
0 
0 
0 
0 
0 
1 
35.4 
4.3 
13.0 
4.3 
4.3 
69.6 
4.3 
23 
1 
3 
1 
1 
16 
1 
Fish-oil/Omacor: 
Omacor:      840 mg x2 
                    840 mg x3 
                    840 mg x4 
                    840 mg x5 
                    840 mg x6 
                    840 mg x8 
                    Unknown 
16.9 
9.1 
0 
9.1 
0 
81.8 
0 
0 
11 
1 
0 
1 
0 
9 
0 
0 
64.6 
9.5 
2.4 
14.3 
4.8 
64.3 
2.4 
2.4 
42 
4 
1 
6 
2 
27 
1 
1 
Ezetimibe: 
Ezetrol:            10 mg 
0 
0 
0 
0 
13.8 
100.0 
9 
9 
Nicotinic acid: 
Niaspan:       2000 mg 
0 
0 
0 
0 
3.1 
100.0 
2 
2 
Resins: 
                      1200 mg 
                      3750 mg 
1.5 
100.0 
0 
1 
1 
0 
1.5 
0 
100.0 
1 
0 
1 
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4.2.2 Lifestyle changes 
As one can see in figure 6, 31 patients reported at their first consultation that they 
never smoked, and just as many said they smoked daily. Regarding degree of 
physical activity, 28 patients answered that they were seldom active. This equals 43 
% of the study population. The majority consumed alcohol, but to a varying degree. 
However, alcohol intake in moderate amounts (1-7 units per week) was most 
frequently reported. The reported lifestyle parameters did not change significantly 
from the first and to the last time the patients were asked how often they smoke, drink 
alcohol and perform physical activity. 
Regarding the 4 participants who did not use any lipid-lowering medications in their 
treatment, their lifestyle changes were not striking either. Only 2 of them made some 
positive changes with respect to their diet, and one of these patients also reduced the 
intake of alcohol. 
Results from the SmartDiet questionnaire (table 13) showed that the majority of the 
patients had a medium score both the first time and the last time they answered the 
questionnaire. The change in total score was not significant (p=0.06). However, 
approximately 37 % obtained a better total score, 50 % the same score and 13 % a 
worse score when considering the change in reported diet. 
Table 13. Results from the SmartDiet questionnaire. 
 SCORE Total 
 1 2 3  
 % n % n % n %  n 
First time 1 16.1 10 72.6 45 11.3 7 100 62 
Last time 2 15.8 6 52.6 20 31.6 12 100 38 
Change 3 13.2 5 50.0 19 36.8 14 100 38 
1 Total score the first time the patients answered the SmartDiet questionnaire. 
2 Total score the last time the patients answered the SmartDiet questionnaire. 
3 Change in total score when comparing results from the first and last time the patients answered the 
questionnaire. Score 1, a worse score; score 2, the same score; score 3, a better score. 
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Figure 6. Frequency of physical activity, smoking and alcohol intake, n=65. 
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4.3 Baseline characteristics and effects of the treatment 
4.3.1 Clinical measurements 
The mean BMI was 29.2 kg/m2 when the participants first came to the Lipid Clinic 
for consultation. Only 14.5 % of the patients had a BMI in the normal range, 50 % 
were overweight and 35.5 % were obese. The waist circumference ranged between 
91–128 cm for the women (n=8), and 95–116 cm for the men (n=19). More 
descriptive information is found in table 14. 
The body weight to the participants did not change significantly following baseline 
(table 15). However, the median blood pressure showed a reduction (table 16). The 
values were significantly lower after 1 and 2 years compared to the baseline values, 
both for systolic and for diastolic blood pressure. 
Table 14. Descriptive information of the patients at their first consultation, n=65. 
Demographics n   
Men/ women 51/ 14   
Age (years) a 65 45.8 (28–73) 
Weight (kg) b 62 90.8 (15.2) 
Height (cm) b 64 176.0 (8.4) 
BMI (kg/m2) b 62 29.2 (4.1) 
Waist (cm) b 27 104.9 (7.4) 
Systolic BP (mmHg) c 57 142.0 (136.0–147.0) 
Diastolic BP (mmHg) c 57 88.0 (86.0–95.0) 
a mean, (minimum–maximum) 
b mean and standard deviation (SD) 
c Median, 95 % confidence interval (CI)  
Table 15. Body weight measures following baseline, mean and SD. 
Time Weight (kg) P-values 
Baseline, n=62 90.8 ± 15.2  
0.5 years, n=20 89.7 ± 15.7 0.885 1 
1 year, n=29 90.7 ± 15.6 0.851 2 
2 years, n=16 95.0 ± 13.1 0.404 3 
3 years, n=11 86.3 ± 14.5  0.479 4 
1 Comparison of weight after 0.5 years with weight at baseline, n=19 
2 Comparison of weight after 1 year with weight at baseline, n=28 
3 Comparison of weight after 2 years with weight at baseline, n=15 
4 Comparison of weight after 3 years with weight at baseline, n=10  
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Table 16. Blood pressure measurements following baseline, median and 95 % CI. 
 Systolic BP (mmHg) P-values a Diastolic BP (mmHg) P-values b
Baseline, n=57 142.0 (136.0–147.0)  88.0 (86.0–95.0)  
0.5 years, n=14 130.5 (121.0–135.0) 0.084 1 83.0 (65.0–93.0) 0.314 1 
1 year, n=23 135.0 (126.0–137.0) 0.012 2 86.0 (84.0–92.0) 0.031 2 
2 years, n=17 130.0 (125.0–138.0) 0.002 3 85.0 (82.0–90.0) 0.035 3 
3 years, n=10 119.5 (110.0–151.0) 0.126 4 80.5 (78.0–89.0) 0.128 4 
a P-values for systolic BP 
b P-values for diastolic BP 
1 Comparison of BP after 0.5 years with BP at baseline, n=13 
2 Comparison of BP after 1 year with BP at baseline, n=21 
3 Comparison of BP after 2 year with BP at baseline, n=15 
4 Comparison of BP after 3 years with BP at baseline, n=7 
 
4.3.2 Blood sample measures 
Table 17 contains information about TG values reported in the referral letters to the 
patients and values measured at baseline at the Lipid Clinic. The TG values measured 
at baseline were not significantly altered compared to the values reported in their 
referral letters. However, when only considering participants with TG values ≥10 
mmol/L in the referral letters, there was a significant reduction at baseline.  
Table 17. TG values at referral compared to baseline values. 
 n Median 95 % CI Minimum Maximum  P-values
TG at referral, mmol/L 54 12.7 (10.4–16.5) 3.3 65.0 0.356 1 
TG ≥10 mmol/L at referral 37 16.9 (13.1–19.3) 10.3 65.0 0.012 2 
TG at baseline, mmol/L 64 12.3 (10.2–15.5) 2.8 57.3  
1 Comparison of TG values measured at baseline with TG values reported in referral letters, n=53. 
2 Comparison of TG values measured at baseline with TG values reported in referral letters to patients who had 
TG ≥10 mmol/L at referral, n=36. 
 
According to the recommended values for blood lipids from the Norwegian 
Medicines Agency (78), only the median total-cholesterol and TG values were 
elevated in the participants at their first consultation at the Lipid Clinic. The median 
concentrations of other blood parameters were within the reference values stated by 
the Clinical chemical division, Oslo University Hospital-Rikshospitalet (131) (table 
18). The minimum TG value was 2.8, and the maximum value was 57.3 mmol/L. 
This represents a huge variation among the participants with respect to TG values at 
baseline. The female participants had significantly higher TG values, measured at 
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their first visit, compared to the males (p=0.011). The median TG value was 18.4 
mmol/L (95 % CI: 10.2–28.8) and 11.4 mmol/L (95 % CI: 8.8–14.1) for the women 
and men respectively. 
Table 18. Blood parameters measured at the start of treatment at the Lipid Clinic. 
Blood parameters n Median 95 % CI Reference 
Glucose, mmol/L 51 5.8 (5.6–6.1) 4.0-6.0 a 
HbA1c, % 44 5.6 (5.4–5.8) 4.5-6.5 a 
Insulin, ρmol/L 26 82.5 (48.0–97.0) 21.0-210.0 a 
C-peptide, nmol/L 35 1.2 (1.0–1.4) 0.3-2.4 a 
Total-cholesterol, mmol/L 62 8.0 (6.9–9.6) <5.0 b 
LDL-cholesterol, mmol/L 35 2.3 (1.9–3.3) <3.0 b 
HDL-cholesterol, mmol/L 58 1.1 (1.0–1.2) >1.0 b 
TG, mmol/L 64 12.3 (10.2–15.5) <2.0 b 
Apo A1, g/L 35 1.2 (1.1–1.3) M:1.1-1.8 / W:1.2-2.3 a 
Apo B, g/L 40 1.0 (0.9–1.1) 0.5-1.3 a 
Lp (a), mg/L 18 114.0 (87.0–315.0) c 
TSH, mIE/L 43 1.8 (1.3–2.2) M:0.5-3.6 / W:0.5-3.4 a 
FT4, ρmol/L 43 13.9 (13.0–14.8) 9.0-21.0 a 
CRP, mg/L 42 2.2 (1.7–2.8) <4.0 a 
ASAT, U/L 47 35.0 (30.0–40.0) M:15.0-45.0 / W:15.0-35.0 a 
ALAT, U/L 52 44.0 (35.0–56.0) M:10.0-70.0 / W:10.0-45.0 a 
CK, U/L 37 116.0 (97.0–158.0) M:<270.0 / W:<150.0 a 
Kreatinin, μmol/L 43 76.0 (70.0–86.0) M:60.0-105.0 / W:50.0-90.0 a 
Pancreas amylase, U/L 27 24.0 (19.0–29.0) 10.0-65.0 a 
 
a Clinical chemical division, Oslo University Hospital-Rikshospitalet. 
b The Norwegian Medicines Agency, therapy recommendations 2003. 
c Clinical chemical division, Oslo University Hospital-Rikshospitalet: 75 % of the population has Lp (a) <300 mg/L 
  M, men; W: women 
 
The TG values measured after 0.5, 1 and 3 years following baseline were 
significantly lower compared to the baseline values (figure 7). In addition, the total-
cholesterol values showed a significantly reduction at all times compared to baseline 
(figure 8). However, despite this reduction, the concentration of both TG and total-
cholesterol were still above the recommended 3 years following baseline. The LDL-
cholesterol and apo A1 values did not change significantly following baseline (figure 
9 and figure 11). However, the HDL-cholesterol and apo B values were significantly 
reduced after one year of treatment (figure 10 and figure 12). More information can 
be found in table 19. 
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Figure 7. TG values at baseline and following baseline, median (95 % CI). 
 
* Significant lower values compared to baseline values.   
a Baseline, measurements taken at the first consultation at the Lipid Clinic 
b 0.5 years, measurements taken 6 months (±3 months) after baseline. 
c 1.0 year, measurements taken 1 year (±3 months) after baseline.  
d 2.0 years, measurements taken 2 years (±3 months) after baseline.  
e 3.0 years, measurements taken 3 years (±3 months) after baseline.  
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Figure 8. Total-cholesterol at baseline and following baseline, median (95 % CI). 
 
* Significant lower values compared to baseline values.   
a Baseline, measurements taken at the first consultation at the Lipid Clinic 
b 0.5 years, measurements taken 6 months (±3 months) after baseline. 
c 1.0 year, measurements taken 1 year (±3 months) after baseline.  
d 2.0 years, measurements taken 2 years (±3 months) after baseline.  
e 3.0 years, measurements taken 3 years (±3 months) after baseline.  
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Figure 9. LDL-cholesterol at baseline and following baseline, median (95 % CI). 
 
a Baseline, measurements taken at the first consultation at the Lipid Clinic 
b 0.5 years, measurements taken 6 months (±3 months) after baseline. 
c 1.0 year, measurements taken 1 year (±3 months) after baseline.  
d 2.0 years, measurements taken 2 years (±3 months) after baseline.  
e 3.0 years, measurements taken 3 years (±3 months) after baseline.  
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Figure 10. HDL-cholesterol at baseline and following baseline, median (95 % CI). 
 
* Significant lower values compared to baseline values.   
a Baseline, measurements taken at the first consultation at the Lipid Clinic 
b 0.5 years, measurements taken 6 months (±3 months) after baseline. 
c 1.0 year, measurements taken 1 year (±3 months) after baseline.  
d 2.0 years, measurements taken 2 years (±3 months) after baseline.  
e 3.0 years, measurements taken 3 years (±3 months) after baseline.  
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Figure 11. Apo A1 values at baseline and following baseline, median (95 % CI). 
 
a Baseline, measurements taken at the first consultation at the Lipid Clinic 
b 0.5 years, measurements taken 6 months (±3 months) after baseline. 
c 1.0 year, measurements taken 1 year (±3 months) after baseline.  
d 2.0 years, measurements taken 2 years (±3 months) after baseline.  
e 3.0 years, measurements taken 3 years (±3 months) after baseline.  
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Figure 12. Apo B values at baseline and following baseline, median (95 % CI). 
 
* Significant lower values compared to baseline values.   
a Baseline, measurements taken at the first consultation at the Lipid Clinic 
b 0.5 years, measurements taken 6 months (±3 months) after baseline. 
c 1.0 year, measurements taken 1 year (±3 months) after baseline.  
d 2.0 years, measurements taken 2 years (±3 months) after baseline.  
e 3.0 years, measurements taken 3 years (±3 months) after baseline.  
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Table19. Blood parameters measured at different times following baseline, median (95 % CI). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P1, Comparison of baseline values and values taken after 6 months (±3 months).  
P2, Comparison of baseline values and values taken after 1 year (±3 months). 
P3, Comparison of baseline values and values taken after 2 years (±3 months).  
P4, Comparison of baseline values and values taken after 3 years (±3 months). 
 Baseline After 0.5 years After 1 year After 2 years After 3 years P1 P2 P3 P4 
Total-cholesterol, 
mmol/L 
n 
8.0 
(6.9–9.6) 
62 
6.2  
(5.0–7.8) 
34 
5.5  
(4.7–6.3) 
42 
5.5  
(4.8–6.4) 
28 
5.8  
(4.7–8.6) 
14 
0.032 
 
32 
<0.001
 
40 
0.032 
 
27 
0.015 
 
13 
LDL-cholesterol,  
mmol/L 
n 
2.3 
(1.9–3.3) 
35 
2.5 
(2.1–3.4) 
23 
2.3 
(1.7–2.8) 
35 
2.2 
(1.4–2.9) 
21 
2.7  
(1.7–3.9) 
14 
0.432 
 
15 
0.911 
 
20 
0.837 
 
11 
0.262 
 
8 
HDL-cholesterol, 
mmol/L 
n 
1.1 
(1.0–1.2) 
58 
1.1 
(0.9–1.3) 
33 
1.0 
(0.9–1.1) 
42 
1.1 
(0.9–1.3) 
24 
1.0  
(0.8–1.3) 
16 
0.299 
 
31 
0.006 
 
37 
0.522 
 
21 
0.059 
 
15 
TG 
mmol/L 
n 
12.3  
(10.2–15.5) 
64 
6.3  
(4.0–9.9) 
33 
4.6  
(3.8–8.3) 
38 
6.5  
(2.3–11.3) 
27 
3.1  
(1.4–11.1) 
15 
0.015 
 
32 
<0.001
 
38 
0.166 
 
27 
0.006 
 
15 
Apo A1 
g/L 
n 
1.2  
(1.1–1.3) 
35 
1.2  
(0.8–1.9) 
8 
1.2  
(1.0–1.3) 
21 
1.3  
(1.0–1.5) 
15 
1.2  
(1.0–1.6) 
8 
0.914 
 
7 
0.418 
 
14 
0.498 
 
7 
0.564 
 
3 
Apo B 
g/L 
n 
1.0  
(0.9–1.1) 
38 
1.0  
(0.5–1.3) 
8 
0.9  
(0.8–1.1) 
22 
0.9  
(0.7–1.1) 
15 
0.9  
(0.7–1.8) 
8 
0.595 
 
7 
0.035 
 
14 
0.131 
 
7 
0.414 
 
3 
Glucose 
mmol/L 
n 
5.8 
(5.6–6.1) 
51 
6.1 
(5.2–6.6) 
18 
6.1 
(5.7–6.5) 
30 
6.7 
(5.6–8.7) 
19 
6.3 
(5.0–13.3) 
10 
0.887 
 
17 
0.466 
 
27 
0.004 
 
18 
0.446 
 
8 
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The TG values to the patients who did not use medications during their treatment at 
the Lipid Clinic are listed in table 20. They all had high or very high TG levels at the 
start of treatment. After consultations at the Lipid Clinic, their TG levels showed a 
reduction, although it was not significant (p=0.068). 
Table 20. TG levels to patients who were not treated medically, n=4. 
First TG 
values1 
(mmol/L) 
Last TG  
values2 
(mmol/L) 
Minimum TG 
values 
(mmol/L) 
Maximum TG 
values 
(mmol/L) 
Reduction in 
TG values 
(%) 
17.9 16.0 16.0 17.9 10.6 
4.9 4.0 1.9 11.2 18.4 
9.8 3.7 3.7 10.9 62.3 
12.4 3.9 3.9 12.4 68.5 
1 The first measured TG values at the Lipid Clinic. 
2 The last measured TG values at the Lipid Clinic taken after minimum 1 month and maximum 3.3 years. 
 
4.3.3 Triglyceride quartiles 
The patients were divided into quartiles according to their first measured TG values, 
and table 21 contains information about clinical findings in the different groups. 
There were no significantly differences between the groups with respect to age, 
weight, BMI, waist or diastolic blood pressure. Only the systolic blood pressure was 
significantly higher in the patients with TG between 10 mmol/L and 20 mmol/L, 
compared with those who had TG ≤10 mmol/L (p=0.008). 
The presence of ≥3 diagnoses in addition to their hyperlipidemia was common in all 
the groups (figure 13). Figure 14 shows the occurrence of those diagnoses which 
varied most between the groups. The conditions not included varied only in a small 
degree, and are therefore not presented in this figure. Hypertension, type 2 diabetes 
and CHD were the most common secondary diagnoses in patients with TG values 
between 20 mmol/L and 30 mmol/L, while alcoholism and pancreatitis were mostly 
seen in patients who had TG values >30 mmol/L. 
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Figure 13. Number of secondary diagnoses in patients divided into quartiles, n=64. 
 
º Patients with TG ≤10 mmol/L at their first consultation, n=23 
¹ Patients with 10< TG ≤20 mmol/L at their first consultation, n=28 
² Patients with 20< TG ≤30 mmol/L at their first consultation, n=6 
³ Patients with TG >30 mmol/L at their first consultation, n=7 
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Figure 14. Specific secondary diagnoses in patients divided into quartiles, n=64. 
 
º Patients with TG ≤10 mmol/L at their first consultation, n=23 
¹ Patients with 10< TG ≤20 mmol/L at their first consultation, n=28 
² Patients with 20< TG ≤30 mmol/L at their first consultation, n=6 
³ Patients with TG >30 mmol/L at their first consultation, n=7 
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Table 21. Characteristics of the patients in each group, median (95 % CI), n=64. 
TG, mmol/L ≤10 n >10 – ≤20 n >20 – ≤30 n >30 n 
TG,  
mmol/L  
6.1  
(4.9–6.9) 
23 14.2  
(12.2–16.2) 
28 25.9  
(21.1–28.8) 
6 43.4  
(36.8–57.3) 
7 
Age, a 
years 
43.0  
(28.0–63.0) 
23 47.5  
(28.0–73.0) 
28 48.5  
(37.0–57.0) 
6 37.0  
(31.0–52.0) 
7 
Weight,  
kg  
89.0  
(83.0–96.0) 
22 89.4  
(84.0–96.0) 
26 83.6  
(79.1–117.0) 
6 96.0  
(60.5–117.0) 
7 
BMI,  
kg/m2 
28.0  
(26.3–31.0) 
22 28.6  
(27.7–29.9) 
26 30.9  
(26.4–38.6) 
6 33.4  
(24.0–36.9) 
7 
Waist,  
cm  
104.0  
(96.0–110.0) 
11 105.5  
(100.0–114.0) 
10 103.0  
(101.0–103.0) 
3 107.0  
(91.0–108.0) 
3 
Systolic BP,   
mmHg 
130.0  
(120.0–145.0) 
19 149.0  
(139.0–154.0) 
24 137.0  
(120.0–168.0) 
5 144.0  
(121.0–160.0) 
6 
Diastolic BP,   
mmHg  
88.0  
(80.0–96.0) 
19 94.0  
(86.0–98.0) 
24 84.5  
(75.0–97.0) 
5 89.0  
(86.0–100.0) 
6 
The patients were divided into quartiles according to their first measured TG values at the Lipid Clinic. 
a Median, (minimum and maximum values) 
 
4.4 Morbidity associated with hypertriglyceridemia 
4.4.1 Coronary heart disease 
In total, 11 participants had a medical history of CHD on referral, and 8 other patients 
experienced a coronary event during the study period (angina pectoris, myocardial 
infarction). Most of the patients with CHD were men (n=14). There was no 
significant difference between those with and without diagnosed CHD with respect to 
total-cholesterol, LDL-cholesterol, TG, apo A1, apo B, CRP or poorly controlled 
diabetes (glucose concentration, HbA1c) (table 22). The HDL-cholesterol 
concentration was significantly lower in patients with CHD (p=0.036). However, in a 
logistic regression this difference disappeared after adjusting for the other blood 
parameters listed in table 22, in addition to age, sex, smoking and hypertension. 
Other risk factors, like smoking was more common in patients without CHD (54.3 %) 
compared to those with diagnosed CHD (42.1 %). However, there was no 
information about the patients smoking history before they started treatment at the 
Lipid Clinic. Regarding blood pressure, the median systolic blood pressure was 143.5 
mmHg (95 % CI: 131.0–152.0) and 142.0 mmHg (95 % CI: 134.0–148.0), and the 
median diastolic blood pressure was 88.0 mmHg (95 % CI: 81.0–94.0) and 88.0 
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mmHg (95 % CI: 86.0–96.0) for those with and without diagnosed CHD respectively. 
The difference between the groups with respect to smoking, systolic and diastolic 
blood pressure was not statistically significant. However, the presence of 
hypertension was 89.5 % versus 45.7 % in those with and without diagnosed CHD 
respectively. This reflects a significantly higher presence of hypertension among the 
patients with CHD (p=0.003). Though, this condition was under medical treatment in 
nearly all these patients.  
Ten of the patients with diagnosed CHD had a primary diagnosis of their 
hyperlipidemia. Seven of these patients had a familial combined hyperlipidemia, 2 
patients a primary mixed hyperlipidemia and one patient a familial 
dysbetalipoproteinemia. Several of those with diagnosed CHD had other secondary 
diagnoses in addition. Nearly the same percentage of patients in both groups had the 
metabolic syndrome, while 53 % suffered from type 2 diabetes compared to 37 % of 
the patients with and without diagnosed CHD respectively. 
Table 22. Blood parameters in patients with and without diagnosed CHD, n=65. 
Blood measures at No CHD CHD  
the start of treatment n Median 95 % CI  n Median 95 % CI  p-value 
Frequency 46   19    
TG, mmol/L  45 11.9 (9.8–15.1) 19 14.1 (7.1–17.8) 0.628 
Cholesterol, mmol/L 44 8.3 (6.9–9.3) 18 7.5 (6.4–10.6) 0.969 
LDL, mmol/L  27 2.3 (1.7–3.5) 8 2.4 (0.7–5.5) 0.576 
HDL, mmol/L  41 1.2 (1.0–1.3) 17 1.0 (0.7–1.1) 0.036 
Glucose, mmol/L  38 5.8 (5.3–6.1) 13 6.0 (5.7–7.2) 0.163 
HbA1c, %  31 5.6 (5.2–5.9) 13 5.7 (5.4–6.2) 0.597 
Apo A1, g/L  25 1.2 (1.1–1.4) 10 1.2 (1.1–1.6) 0.815 
Apo B, g/L  26 1.0 (0.9–1.2) 12 0.9 (0.7–1.2) 0.087 
CRP, mg/L 31 2.1 (1.6–2.8) 11 2.6 (1.4–9.3) 0.146 
 
 
4.4.2 Pancreatitis 
Among the participants with pancreatitis (n=11), 27.3 % had a chronic type, 36.4 % 
had experienced an acute pancreatitis, while 36.4 % had experienced recurrent 
episodes of acute pancreatitis. The median TG value was highest in the group of 
patients with recurrent acute pancreatitis, and lowest in the group that never had 
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suffered from pancreatitis (table 23). There was a significant difference in TG values 
between the patients without experienced pancreatitis and patients who had suffered 
from either an acute, recurrent acute or chronic pancreatitis (p<0.001). However, 
there was no significant difference in TG values between the groups of patients with 
different types of pancreatitis. 
Table 23. TG values in patients with and without pancreatitis, n=65. 
 n Median a 
mmol/L  
95 % CI  
mmol/L 
Minimum 
mmol/L 
Maximum 
mmol/L 
P-value 
No pancreatitis 54 8.2 (7.5–10.2) 2.1 25.3 <0.001 b 
Pancreatitis 11 22.1 (11.9–39.8) 6.2 47.4 0.492 c 
-acute  4 17.1 (11.9–25.4) 11.9 25.4  
-recurrent  4 29.5 (14.0–47.4) 14.0 47.4  
-chronic  3 22.6 (6.2–35.0) 6.2 35.0  
 
a To show a condensed view, the results in this table are based on the mean TG values to all the participants.  
Some patients had 2 TG measures, while others had several measures, and therefore we chose to estimate the  
mean TG value to the participants, and use these values to compare those with and without pancreatitis.  
The median in this table therefore refers to the median of all the mean TG values estimated for the participants. 
b Comparison of mean TG values in patients with and without pancreatitis. 
c Comparison of mean TG values in patients with acute, recurrent acute and chronic pancreatitis. 
 
Only half of the study population (n=33) had measured the concentration of pancreas 
amylase one or several times while they were patients at the Lipid Clinic. Thirty 
percent of these patients had experienced pancreatitis. However, one of the patients 
with recurrent pancreatitis had never measured the concentration of pancreas 
amylase, although this patient came to regular controls at the Lipid Clinic for 6 years. 
Only 2 of the participants with reported pancreatitis had higher values of pancreas 
amylase than recommended. They both had a chronic pancreatitis, and one of them 
was an alcoholic. The median concentration of pancreas amylase was lowest in those 
without pancreatitis compared to those with a medical history of pancreatitis (table 
24). However, there was no significant difference in the concentration of pancreas 
amylase between those with and without pancreatitis or between the patients with 
acute, recurrent acute and chronic pancreatitis. 
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Table 24. Pancreas amylase values in patients with and without pancreatitis, n=33. 
 n Median a
U/L 
95 % CI 
U/L 
Minimum
U/L 
Maximum 
U/L 
P-value 
No pancreatitis 23 23.0 (17.0–24.5) 10.0 47.0 0.074 b 
Pancreatitis 10 33.5 (15.0–47.5) 8.5 73.0 0.786 c 
-acute 4 26.5 (19.0–40.0) 19.0 40.0  
-recurrent 3 39.0 (15.0–47.5) 15.0 47.5  
-chronic 3 47.3 (8.5–73.0) 8.5 73.0  
 
a To show a condensed view, the results in this table are based on the mean values of all the measures of  
pancreas amylase for each patient. Some patients had 2 measures, while others had several measures, and  
therefore we chose to estimate the mean value of pancreas amylase for all the participants, and use these  
values to compare those with and without pancreatitis. The median in this table will therefore refer to the median  
of all the mean values estimated for the participants. 
b Comparison of mean values of pancreas amylase between those with and without pancreatitis. 
c Comparison of mean values of pancreas amylase between the patients with acute, recurrent acute and chronic pancreatitis.
 
Four of the participants in the present study were diagnosed as alcoholics, and all of 
them had suffered from pancreatitis. One had experienced an episode of acute 
pancreatitis, another had suffered from recurrent episodes of acute pancreatitis, while 
two persons suffered from a chronic type. Although not diagnosed as an alcoholic, 
the alcohol intake might have been high in the other patients with pancreatitis as well. 
However, there was no significant difference in self-reported alcohol intake among 
those with and without pancreatitis in the present study (figure 15).   
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 Figure 15. Mean alcohol intake among those with and without pancreatitis, n=65. 
 
*No pancreatitis, n=54 
**Pancreatitis, patients with a medical history of acute, recurrent acute or chronic pancreatitis, n=11 
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Six of the patients with pancreatitis had a primary hyperlipidemia, either type IIb or 
type V (table 25). One of the patients with type IIb hyperlipidemia was a woman 
trying to get pregnant. She had experienced several episodes of acute pancreatitis 
before she came to the Lipid Clinic, probably as a result of her hypertriglyceridemia. 
This female participant was followed up for approximately 6 years at the Lipid 
Clinic. During this period she had 4 spontaneous abortions and one abrupt pregnancy 
because of neural tube defect. Her primary hyperlipidemia probably made her 
especially susceptible for developing pancreatitis during pregnancy. However, this 
female participant did have two pregnancies with successful outcome, despite the 
development of acute pancreatitis in week 35 in one of these pregnancies.   
Nearly all of the participants with pancreatitis had one or several secondary 
conditions in addition (table 26). The most common diagnosis in addition to the 
hyperlipidemia in patients with pancreatitis was type 2 diabetes, which was present in 
54.5 % of the patients. However, the occurrence of type 2 diabetes was not 
significantly more present in those with pancreatitis compared to those without this 
condition. 
Table 25. Primary diagnoses in addition to pancreatitis, n=11. 
Type of pancreatitis Type of primary hyperlipidemia a 
 Type IIb Type III Type IV Type V 
Acute/recurrent acute (n) 1 0 0 2 
Chronic  (n) 2 0 0 1 
Total (n) 3 0 0 3 
 
a The table does not include type I and type IIa hyperlipidemia because none of the participants in the present 
study were registered with these types.  
 
Table 26. Secondary diagnoses in addition to pancreatitis, n=11. 
Type of pancreatitis Number of secondary diagnoses  
 0 1 2 ≥3 
Acute/recurrent acute (n) 2 1 3 2 
Chronic  (n) 0 0 0 3 
Total (n) 2 1 3 5 
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5. Discussion 
5.1 The method 
5.1.1 Study design 
The present study was retrospective, and this study design has both advantages and 
disadvantages. For instance, retrospective studies are often more easy and cheaper to 
perform since the data is already existing. However, this design might have a lower 
grade of scientific evidence than for instance prospective studies, partly because 
important data might be missing from medical records, and such data can be difficult 
to retrieve.  
5.1.2 Study population 
Patients with TG ≥10 mmol/L at the start of treatment were first meant to be eligible 
for the present study. However, to increase the number of participants in the study, 
the inclusion criteria were changed to patients who had TG ≥10 mmol/L at some 
point during their treatment time at the Lipid Clinic.  
Informed consent was given by 58 % of the patients who fulfilled the inclusion 
criteria. There were several reasons for why the remaining did not want to participate. 
Some were not interested because they did not accomplish any benefits from the 
participation personally. Several patients said they would return the informed 
consent, but never did. One patient returned it without signature, but accompanied by 
a letter which stated that the patient was not satisfied with the public health service, 
and would therefore not help us. Others gave no specific reasons for why they did not 
want to participate. Fourteen patients were not reachable by phone. In addition, one 
consent was received in late April, but this patient was not included in the study 
because of the late response.  
The majority of the participants were men. Abdominal obesity has been found to be 
significantly associated with hypertriglyceridemia, and this fat distribution is more 
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frequently seen in men compared to women (132). Despite of this, the few female 
participants in the present study had significantly higher TG values at the start of 
treatment compared to the male participants. However, the fact that there was a 
predominance of male participants indicates that severe hypertriglyceridemia might 
be a larger problem among men compared to women. This is also supported by 
another Norwegian study where 86 % of the individuals with TG values ≥10 mmol/L 
were men, and 14 % were women (Anja Schou Lindman, National Public Health 
Institution, personal communication). 
5.1.3 Limitations 
The study was not planned in advance before the included participants started 
treatment at the Lipid Clinic. This leads to several limitations. The notes in the 
medical records were written by different doctors and nutritionists, and the contents 
varied with respect to kind of information and how comprehensive the information 
was. Consequently, the medical records contained different amount and type of 
information for each patient, and also for the same patient at different consultations. 
The time between each consultation and the length of follow-up time at the Lipid 
Clinic was highly variable. Data on several variables included in this study were 
therefore lacking or incomplete for many of the participants. Waist circumference 
was one clinical measure there was little information about, and analyses concerning 
alteration in this parameter were therefore not performed. Lacking data is therefore a 
weakness in the present study.  
Since nearly all the participants received both medical treatment and lifestyle 
recommendations while they were patients at the Lipid Clinic, it was difficult to 
estimate how great effects the respective treatment strategies had on the treatment 
outcome. Treatment results were therefore only possible to interpret as an effect of 
the two treatment strategies in combination.  
The SmartDiet questionnaire existed in 2 different editions in the period 2002-2007. 
Some of the participants might therefore have used both editions. Only the total 
scores were taken into consideration, since it was difficult to compare scores on 
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specific questions for many of the participants. Unfortunately, the SmartDiet 
questionnaire is not available in the medical records, which contributes to difficulties 
in detecting specific changes in the diet to the patients. This highlights the importance 
of including this questionnaire in the medical records of the patients in the future. In 
addition, the newest edition of the SmartDiet questionnaire differs from the oldest in 
that it does not include the question regarding intake of sugar, snacks, and sweets in 
the total score. Patients who used both editions might therefore have made positive 
changes in their diet regarding intake of sugary food, without being detected and 
acknowledged in the present study.  
Some patients did not take any clinical measurements, blood samples or did not 
answer the SmartDiet questionnaire following baseline. It was therefore impossible to 
consider the treatment effects for the whole study population with respect to changes 
in these parameters.     
Information about TG and pancreas amylase values in the period before an episode of 
pancreatitis was difficult to obtain for many of the patients. Instead, the mean values 
for both TG and pancreas amylase were estimated for all the participants. However, 
these values do not represent the actual values before an episode of pancreatitis, and 
only give an impression of the patients with respect to these parameters.  
The lack of data is also a problem which affects the statistical analyses and 
presentation of the results. When interpreting the figures and results in the present 
study, it is important to consider that the mean and median values for the parameters 
measured at different times are not related to exactly the same group of individuals.   
The data material and analyses would probably have been more comprehensive and 
complementary if the study was planned before the included patients started 
treatment at the Lipid Clinic. It would also have been an advantage if the 
doctors/nutritionists followed the same standardised way of writing notes in the 
medical records. 
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5.2 The results 
5.2.1 Diagnoses 
Results from the present study showed that 43 % of the participants had a recorded 
primary diagnosis based on the Fredrickson classification of hyperlipidemias, while 
the rest only had secondary diagnoses that might explain their hyperlipidemia. This 
distribution is somewhat equal to the one found in a study conducted by Chait and 
Brunzell (133). They evaluated the role of familial and secondary factors in the 
etiology of severe hypertriglyceridemia in 54 patients. Familial factors were detected 
in 48 % of them, while only secondary factors were detected in the rest of the 
patients. However, these results characterized patients with even higher TG values (> 
22.5 mmol/L) than in the present study.  
Primary hypertriglyceridemia 
In the present study, familial combined hyperlipidemia was found to be the most 
prevalent primary diagnosis which contributed to the hyperlipidemia in the 
participants. This correlates with other literature on this condition, which states that 
familial combined hyperlipidemia is considered as one of the most common genetic 
hyperlipidemias in the general population (26).  
Nearly all of those with a primary diagnosis in the present study had one or several 
secondary diagnoses in addition. These secondary conditions might have contributed 
to even higher TG values, since the combination of familial and secondary causes of 
hypertriglyceridemia has been shown to interact and result in a marked elevation of 
TG (133). In addition, some of the primary diagnoses of hyperlipidemia need 
secondary factors for expression (30). In persons with a known genetic disorder it is 
therefore important to consider secondary conditions which also may contribute to 
the dyslipidemia.  
Several similarities, like an increased concentration of VLDL, can make it difficult to 
distinguish properly between the different types of hyperlipidemias. In the present 
study, information about relatives with respect to lipid levels and CHD were 
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incomplete or lacking for several participants. This can result in erroneous or 
uncertain diagnosis, which has to be taken into consideration.        
Secondary hypertriglyceridemia 
Among the secondary diagnoses registered in the present study, nearly all of them can 
be related to the presence of hyperlipidemia. While most of the conditions might lead 
to elevations in TG values, some of the conditions might also have developed as a 
consequence of this lipid abnormality.  
Nearly all of the participants (96.9 %) in the present study had one or several 
secondary diagnoses. The fact that the main part had ≥3 secondary conditions implies 
that these patients represent a group with considerably morbidity. The presence of at 
least one secondary diagnosis in addition to the hyperlipidemia has earlier been found 
to be very common. Ninety-four percent of the individuals in the study by Chait and 
Brunzell had potential secondary causes to their hypertriglyceridemia (133). 
Furthermore, dyslipidemia has earlier been reported to be developing more often 
secondary to different conditions rather than due to a primary genetic defect alone 
(25). The fact that patients with hypertriglyceridemia often have other conditions in 
addition substantiates the importance of these disorders in the development of 
hypertriglyceridemia, as well as in the treatment of hypertriglyceridemia.  
There is no consensus about the use of a specific definition when diagnosing the 
metabolic syndrome (134). The definition from the International Diabetes Federation 
is more strict with respect to measures of the waist circumference. Information about 
this parameter was lacking for many of the patients in the present study, and the 
definition from the National Cholesterol Education Program was therefore more 
suitable. In addition, this definition might be favourable because some patients can 
develop multiple metabolic risk factors when the waist circumference is only 
marginally increased (6). The occurrence of the metabolic syndrome might be 
somewhat different in a study population depending on the chosen definition. 
However, an earlier study where the definitions from the International Diabetes 
Federation and the National Cholesterol Education Program were compared 
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concluded that both definitions identified approximately the same group of 
individuals (134). The metabolic syndrome was the most prevalent condition seen in 
the present study. This was not surprising since all the patients had elevated TG 
levels, and this lipid abnormality is an important component of the metabolic 
syndrome. Hypertriglyceridemia has earlier been detected in more than 3/4 of patients 
with the metabolic syndrome (135). The high percentage of patients with 
hypertension in the present study can also be seen in relation to the occurrence of the 
metabolic syndrome, since hypertension is another important component of this 
syndrome.  
Type 2 diabetes was another common secondary diagnosis seen in the present study 
(41.5 %). This is consistent with earlier studies where untreated diabetes mellitus was 
the most common potential secondary cause of hypertriglyceridemia, either alone or 
in combination with another potential secondary cause (ethanol, estrogen) (133). The 
relation between hypertriglyceridemia and type 2 diabetes has been shown in earlier 
studies where fasting plasma TG and VLDL values were raised in both male and 
female diabetics (136). Results from a Norwegian study report that 1.6 % of men with 
TG >5 mmol/L and <10 mmol/L have diabetes, or a history of diabetes. In addition 
will 4.5 % of men with TG ≥10 mmol/L and <20 mmol/L, and 10.5 % of men with 
TG ≥20 mmol/L report the same thing. For women, the respective numbers are 4.3 %, 
9.3 % and 33.3 % (Anja Schou Lindman, National Public Health Institution, personal 
communication). These results indicate that the presence of type 2 diabetes and 
hypertriglyceridemia increase in accordance with each other. However, this supports 
a strong link between the glucose and TG metabolism, which has been stated many 
times earlier as well (39).  
Alcohol consumption has also been connected to elevated plasma TG levels (56). 
Only 6 % of the participants were diagnosed as alcoholics in the present study. In 
comparison, an earlier study found that ethanol was the secondary cause in 11 % of 
the individuals examined with hypertriglyceridemia (133). However, the alcohol 
consumption might have been high among the other participants in the present study, 
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although not diagnosed as alcoholics. Alcohol intake as a contributing factor to the 
hyperlipidemia in the participants might therefore have been underestimated.  
The present study found a higher occurrence of some of the secondary conditions 
compared to earlier studies. For instance, hypothyroidism and kidney disease were 
present in 15 % and 6 % of the patients respectively, while hypothyroidism was only 
seen in 1.8 % and renal failure in 1.8 % of the individuals in an earlier study (133). 
However, the patients in that study had higher TG values (>22.5 mmol/L) compared 
to the patients in the present study. This can imply that hypothyroidism and kidney 
disease as contributing factors to hypertriglyceridemia usually does not lead to such 
extreme TG values as seen in that study. In addition, the present study registered 
patients with different kinds of kidney disease, not only patients with renal failure. 
This might also be a contributing factor to the higher occurrence of this condition in 
the present study. 
When dividing the participants into quartiles according to their TG values, it became 
clear that the occurrence of different secondary conditions increased with higher TG 
values. The percentage of patients with ≥3 secondary diagnoses was high in all the 
groups, though it was clearly highest among the patients with TG values between 20 
mmol/L and 30 mmol/L. This substantiates the fact that the presence of secondary 
diagnoses most likely had a strong effect on the TG values to the participants, and 
that several conditions in combination might have an additive or even a synergistic 
effect on the TG values.   
5.2.2 Treatment of hypertriglyceridemia 
Nearly all of the participants received medical treatment and they all got advice 
regarding diet and lifestyle when they were patients at the Lipid Clinic. It is difficult 
to say if the medication or the lifestyle recommendations had the greatest treatment 
effect. Most likely, the combination of both was responsible for the treatment results 
seen in the participants.  
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Medication  
After the participants came to the Lipid Clinic, there was a significant increase in the 
use of medications which confirms that this is an important part of the treatment 
strategy in patients with hypertriglyceridemia at the Lipid Clinic. The majority of the 
patients used several medications in combination. At the end of treatment, the 
combination of a statin and Omacor was the most prevalent, and this combination 
might also have been very effective in these patients. Studies have shown that fish 
oil/statin combination in mixed hyperlipidemia has an additive effect, and might 
cause a greater TG reduction compared to fish oil or a statin used alone (137). In 
addition, 27.7 % of all the participants used a combination which included a statin 
and a fibrate. Studies have shown that patients with combined dyslipidemia, may 
benefit from such a combination (82). However, the drawback is that statins increase 
the risk of rhabdomyolysis, and this risk can be exacerbated with concomitant use of 
fibrates. For instance, gemfibrozil alters the statin metabolism and increases the 
plasma concentration of this medication (138). The Food and Drug Administration 
have reported several cases of severe myopathy and rhabdomyolysis with the 
concomitant use of lovastatin and gemfibrozil (139). There were no registered 
episodes of rhabdomyolysis among the patients who used a combination therapy in 
the present study. However, 4 of the participants complained about muscle and 
skeletal pain. This description was a bit vague, and could be a symptom of many 
conditions. None of these patients used a statin and a fibrate at the same time, so most 
likely this pain did not reflect a side effect of such a combination. Though, all four 
had used statins when they came to the Lipid Clinic, or during their treatment there. 
However, it is important to follow up patients who use statins, or a combination of 
statins and fibrates, with respect to adverse side effects. 
Several patients used other medications as well that might have had an adverse effect 
on their TG level, for instance antihypertensive medications and resins. An earlier 
study compared one group of men who used diuretics with another group who did not 
use any antihypertensive medications (67). Results showed that the mean change in 
TG values was 0.12 mmol/L after one year of treatment with diuretics in doses up to 
100 mg per day, while the mean change in TG values in the group who did not use 
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diuretics was -0.27 mmol/L. This difference between the two groups was significant. 
However, the effects of the diuretics on the TG values were small, and most likely the 
use of antihypertensive medications in the present study can not explain the high TG 
values in the patients, at least not as the only contributing factor. Resins are 
medications which usually have been restricted to patients with hypercholesterolemia, 
and advised not to be used in patients with hypertriglyceridemia (86). The 5 patients 
who used resins in the present study used other lipid-lowering medications in 
addition. Though, they did not use resins as a result of intolerance of other 
medications. Information regarding why these patients used resins in their treatment 
was not registered in their medical records. The impact this medication actually had 
on their lipid levels was difficult to estimate, among other things because of 
simultaneous use of other medications. 
The treatment led to a significant reduction in median total-cholesterol and TG values 
following baseline. This reduction might indicate an effective medication at the Lipid 
Clinic, although the participants did not reach the recommended values. However, a 
common problem that must be considered is the compliance to treatment. It is 
difficult to measure compliance, but a review of patient adherence to treatment 
estimates that poor compliance is to be expected in 30-50 % of all patients, 
irrespective of disease, prognosis and setting (140). This problem was also seen in the 
present study, where some of the patients reported not to take their prescribed 
medications. Reasons were shortage of money, forgetfulness and lack of 
understanding of the importance of these medications. Poor compliance will have 
huge impacts on the treatment result, and better treatment effect would maybe have 
been accomplished if all the patients followed their prescribed treatment. To combat 
this problem it is important that doctors give thoroughly information to the patients to 
make sure they realise the importance of the treatment.      
Lifestyle and diet  
At the start of treatment, almost 50 % of the participants reported that they smoked on 
a daily basis. This result is consistent with another Norwegian study which reported 
that 58.5 % men and 59.2 % women with TG ≥10 mmol/L smoked daily (Anja Schou 
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Lindman, National Public Health Institution, personal communication). However, 24 
% of the Norwegian population (≥16 years) reported of daily smoking in 2005 (141). 
This indicates that daily smoking is much more common among persons with 
hypertriglyceridemia compared to the population in general. This habit might be a 
strong contributing factor in the etiology of their hypertriglyceridemia.  
Most of the patients reported a moderate alcohol intake. Many studies have shown an 
association between alcohol intake, even in moderate amounts, and lipid levels (142). 
However, these results are not entirely consistent. For instance, a Norwegian study 
showed that consumption of a glass of red wine daily had no significant effect on the 
TG concentration (143). Underreporting of alcohol intake might be a problem in the 
present study, and has to be taken into consideration. 
A large part of the study population (43 %) reported that they seldom performed 
physical activity. This percentage of inactive patients was nearly 3 times higher than 
in the general population where inactivity is reported to be 15 % among individuals 
aged 25-66 years (141). Since the data were missing for 11 participants at the end of 
treatment, it was difficult to evaluate if there was an increase, a reduction or no 
change at all in this inactive lifestyle. However, this lifestyle change is especially 
essential since it is well known that exercise is one of the most important non-
pharmacologic ways to reduce the level of TG (144). In a study by Wirth et al. they 
found that the TG concentration decreased with 25 % following endurance physical 
training in male participants with hypertriglyceridemia, compared to the control 
group with sedentary males with hypertriglyceridemia (145).  
Regarding the diet, there was a strong trend indicating improvements in their reported 
diet following baseline. This might indicate an effect of the dietary counselling they 
received at the Lipid Clinic, though no information existed on potential counselling 
other places. The improvements in the diet might have been a contributing factor to 
the positive alterations seen in the lipid levels. Other studies also support the fact that 
diet modifications can have positive effects on the lipid levels. In a study by Man et 
al, dietary counselling in patients with hypertriglyceridemia was effective in reducing 
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the lipid levels (146). The TG and cholesterol levels were reduced with 31 % and 15 
% respectively after 3 months.  
Despite recommendations for lifestyle changes, including physical activity, alcohol 
intake and smoking, there were only small alterations following baseline in these 
parameters. The lack of significant changes might reflect that the patients did not 
understand the importance and effect these alterations might have on their lipid levels 
and health profile. Lifestyle changes are also hard to make, and patients need lots of 
motivation and encouragements to achieve these changes. This reflects the 
importance of regular follow-up consultations at for instance the Lipid Clinic or at 
their general practitioner. Although not significant, the accomplished alterations 
might still be of importance. Four of the participants did not use any medications 
during their time at the Lipid Clinic. Reasons for why these patients did not receive 
lipid-lowering medications were not documented. In addition, the changes in reported 
lifestyle habits and diet were small also for these patients. Still, their TG levels 
decreased following baseline with minimum 10.6 % and maximum 68.5 %. Though, 
this might indicate that even small changes with respect to lifestyle and diet can be of 
importance in the management of hypertriglyceridemia. 
5.2.3 Baseline characteristics and effects of the treatment 
Clinical measurements 
Most participants were overweight (50 %) or obese (35.5 %) at the start of treatment 
at the Lipid Clinic. Results from another Norwegian study also showed that 
overweight was common in persons with hypertriglyceridemia. In this study the mean 
BMI for men with TG levels ≥10 mmol/L and <15 mmol/L was 29.1 kg/m2, for those 
with TG levels ≥15 mmol/L and <20 mmol/L it was 30.4 kg/m2, and when the TG 
levels were ≥20 mmol/L the mean BMI was 28.9 kg/m2. The respective results for the 
female study population were 29.7 kg/m2, 32.2 kg/m2 and 27.1 kg/m2 (Anja Schou 
Lindman, National Public Health Institution, personal communication). These results 
indicate that overweight and obesity are greater problems among patients with 
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hypertriglyceridemia than in the general population, where overweight was found in 
34 %, and obesity was found in 9 % of the population (≥16 years) in 2005 (141).  
In the same way as studies have shown a relation between overweight and 
hyperlipidemia, weight reduction has also shown to result in lower levels of TG 
(147). Unfortunately, there was no significant change in weight among the 
participants in the present study following baseline. Therefore, weight alteration was 
most likely not a contributing factor in the improvements of the lipid levels. 
Blood parameters  
It usually takes 3 months from referral until the patient gets a consultation at the 
Lipid Clinic. The significant reduction in TG levels at baseline compared to the 
referral values indicates that the patients who had very high TG levels (≥10 mmol/L) 
at referral (n=37) probably had made some lifestyle improvements before they came 
to the Lipid Clinic. In addition, some of these patients were also started on lipid-
lowering medications by their general practitioner.   
When considering all the included participants, there was a significant reduction in 
the concentration of total-cholesterol and TG following baseline. Both total-
cholesterol and TG concentrations were still above the recommended values 3 years 
after baseline. However, complete normalization of TG values is reported elsewhere 
to rarely be achieved in patients with severe hypertriglyceridemia (79). Though, the 
lack of weight reduction, in addition to insufficient changes in lifestyle and diet habits 
might be explanatory factors for why the patients did not achieve even more profound 
reductions in their lipid levels. Although most of the patients used medications in 
their treatment, the type, dose and combination might not have been optimal in 
reducing their lipid values. 
5.2.4 Morbidity associated with hypertriglyceridemia 
Coronary heart disease 
In the present study, 11 of the 65 participants had a medical history of CHD at 
referral. In addition, 8 other patients experienced a coronary event during the study 
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period. Hypertriglyceridemia is now recognised as an independent risk factor for 
CHD, and several epidemiological studies have shown an association between 
elevated plasma TG levels and increased CHD risk (113). However, other important 
risk factors were also present in many of the patients in the present study, for instance 
smoking, physical inactivity and an unhealthy diet. Most likely, the combination of 
several of these factors was responsible for the morbidity in these patients. Lifestyle 
changes and start-up with medications in the participants at the Lipid Clinic might 
have prevented future CHD in several of the participants.  
Self-reported cardiac infarction has earlier been reported in 1.1 % of men with TG >5 
mmol/L and <10 mmol/L, in 2.4 % of men with TG ≥10 mmol/L and <20 mmol/L 
and in 5.3 % of men with TG ≥20 mmol/L. All these men were in the age of 40-43 
years (Anja Schou Lindman, National Public Health Institution, personal 
information). Although these results do not include women, the occurrence of CHD 
was much lower in that study compared to the present study. However, the present 
study included patients with all types of CHD, not only those with heart infarction. In 
addition, these two study populations might also differ with respect to the presence of 
other risk factors. Still, these results indicate that TG values and the occurrence of 
heart infarction/CHD increase in accordant with each other.  
The most common primary hyperlipidemia in the patients with diagnosed CHD was 
familial combined hyperlipidemia. This finding is supported by other studies which 
consider this type as the most frequently genetic hyperlipidemia seen in patients 
affected by CHD (26). A prospective study of hypertriglyceridemic families 
demonstrated that first-degree relatives of probands in families with familial 
combined hyperlipidemia were at statistically significant increased risk of CVD 
mortality (70 %) compared to control subjects (148). Three other patients with CHD 
in the present study also suffered from primary hyperlipidemias associated with 
increased CHD risk.  
 92
Pancreatitis 
In the present study, 11 of the 65 participants had experienced pancreatitis, and 8 of 
these had experienced one or several acute episodes during the study period. None of 
the patients in the present study were registered with a history of gallstone, which is 
the most important risk factor for developing pancreatitis (118). Alcohol is also 
reported as a risk factor in earlier studies (119), and 4 of the patients with pancreatitis 
in the present study were also alcoholics. In general, patients with experienced 
pancreatitis did not report a higher alcohol intake than patients without this condition. 
In fact, it seemed like the patients with experienced pancreatitis had a lower mean 
alcohol intake, although not significantly. This might indicate that the patients with 
pancreatitis had reduced their alcohol intake following an experienced episode of 
pancreatitis. It can also mean that a high alcohol intake was not the causative factor of 
the episodes in the present study. However, underreporting of alcohol intake is also a 
potential problem that has to be considered. 
Hypertriglyceridemia has been reported in earlier studies to be the most common 
cause of acute pancreatitis not due to gallstone or alcohol (149). In the present study, 
the patients with pancreatitis had a median TG value of 22.1 mmol/L while the 
patients without experienced pancreatitis had a median TG value of 8.2 mmol/L. The 
fact that there was a significant difference in TG values between patients with and 
without pancreatitis might indicate that a high TG value could have been the 
causative factor in some of the patients with pancreatitis. In addition, acute and 
recurrent episodes of acute pancreatitis were the most common types of this condition 
in the present study. Earlier studies have concluded that pancreatitis due to 
hypertriglyceridemia usually presents either as one episode or recurrent episodes of 
acute pancreatitis, and rarely as chronic pancreatitis (122).   
One of the patients with type IIb hyperlipidemia experienced several abortions, 
probably due to the development of acute pancreatitis in the pregnancies. This is 
reported to be an uncommon complication of pregnancy, but her pre-existing 
abnormality in the lipid metabolism may have been exacerbated during pregnancy 
and caused gestational hyperlipidemic pancreatitis (61). 
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All the participants with either acute or recurrent acute pancreatitis had one or several 
secondary diagnoses, with exception of 2 patients. Acquired forms of 
hypertriglyceridemia are reported not to cause a significantly elevation in TG 
concentration to be a risk factor for pancreatitis. However, in the presence of an 
underlying abnormality in the lipoprotein metabolism, the secondary conditions 
might increase the TG concentration to a level which might result in pancreatitis 
(122). Type 2 diabetes was the most common secondary condition in patients with 
pancreatitis in the present study. This might indicate that type 2 diabetes in patients 
with hypertriglyceridemia is an especially important secondary condition to consider, 
when evaluating the risk of pancreatitis. This is supported by an earlier cohort study 
which found that patients with type 2 diabetes had a 2.83-fold greater risk of 
pancreatitis compared to patients without diabetes (150).  
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6. Conclusion 
The main results in the present study were: 
(i) Twenty-eight patients had a registered primary diagnosis in their medical 
records which could explain their hyperlipidemia, and type IIb 
hyperlipoproteinemia (familial combined hyperlipidemia) was the most 
common type. More than 60 % of the participants had ≥3 diagnoses in 
addition to their hyperlipidemia. In the present study, the metabolic 
syndrome, hypertension and type 2 diabetes were the most common 
secondary conditions seen among the participants.  
(ii) Nearly all the patients used medications in their treatment at the Lipid 
Clinic, and they all received recommendations for lifestyle improvements. 
There was a significantly increase in the use of medications after start of 
treatment at the Lipid Clinic. The lifestyle parameters did not change 
significantly over time compared with baseline.  
(iii) Most of the participants were overweight or obese at the start of treatment 
at the Lipid Clinic. Regarding blood parameters, only total-cholesterol and 
TG values were elevated above the recommended at baseline. The 
treatment had a positive effect on the lipid levels and the blood pressure to 
the participants. However, the treatment had no significant effect on their 
body weight. 
(iv) Among all the participants, 29 % were diagnosed with CHD and 17 % had 
experienced one or several episodes of acute pancreatitis, or had a chronic 
pancreatitis.  
Patients with hypertriglyceridemia represent a group which are affected by morbidity 
in a large degree. A future challenge is to identify untreated patients with 
hypertriglyceridemia and initiate an effective treatment to reduce their risk for 
complications like CHD and acute pancreatitis. 
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Appendix 1. Approval from the Regional Committee for Medical Research Ethics 
Overlege dr.med. Kjetil Retterstel 
Lipidklinikken 
Rikshsopitalet-Radiumhospitalet HF 
Dato: 30.06.08 
Deres ref.: 
Regional komite for medisinsk og helsefaglig 
forskningsetikk Sor-0st A (REK Sor-0st A) 
Postboks 1130 Blindem 
NO-0318 Oslo 
Telefon: 22 84 46 66 
Telefaks: 22 85 05 90 
E-post: jorgen.hardang@medisin.uio.no 
Nettadresse: www.etikkom.no 
Var ref.: S-08337a, saksnummer: 2008/8674
 
S-08337a Alvorlig hypertriglyseridemi: Arsaker og behandling [6.2008.1118]
 
~	 Vi viser til brev datert 18.6.08 med informasjonsskriv med samtykkeerklrering vedlagt. 
Komiteen har ingen merknader til revidert informasjonsskriv med samtykkeerklrering. 
Komiteen godkjenner at prosjektet gjennomferes. 
Med vennlig hilsen 
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r:v 
Kristian Hagestad 
Fylkeslege cand.med., spes. i samf.med 
Leder 
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Komitesekretrer 
-
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Appendix 2. Approval from the Data Inspectorate 
NOTAT
 
Til:
 
Kopi:
 
Fra:
 
Saksbehandler:
 
Dato:
 
Offentlighet:
 
/'""'.Sak: 
Kjetil Retterst0l, overlege, Lipidklinikken 
Ingvild Veseth, student, DiO 
Aksel Sogstad, personvemombud 
13. august 2008 
Ikke unntatt offentlighet 
08/3914: Tilnldning av forskningsstudie unntatt 
konsesjon 
IT-avdelingen 
Bes0ksadr: Forskningsveien 2 B, Oslo 
Postadr: Rikshospitalet HF, 0027 Oslo 
Sentralbord: 23 07 00 00 
Direktelinje: 23 07 50 34 
Epost: firmapost@rikshospitalet.no 
personvern@rikshospitalet.no 
Tilradning til innsamling og databehandling av personopplysninger i forskningsstudien 
"Alvorlig hypertriglyseridemi: Arsaker og behandling" 
Personvemombudet har vurdert det til at den planlagte databehandlingen av personopplysninger 
tilfredsstiller forutsetningene for melding gitt i personopplysningsforskriften § 7-27 og derfor er 
unntatt konsesjon. Personvemombudet har myndighet til a foreta denne avgj0relsen pa vegne av 
Datatilsynet. 
Det tilras at prosjektet igangsettes med f0lgende betingelser: 
. • Data lagres avidentifisert pa en av sykehusets forskningsservere (O:Forskning, 
Forskemett eller Medlnsight). Annen lagringsform forutsetter gjennomf0ring av en 
~ risikovurdering som rna godkjennes av personvemombud. Se referanser. 
•	 Kryssliste som kobler avidentifiserte data med personopplysninger lagres separat pa 
prosjektleders avlaste kontor. 
•	 Data slettes eller anonymiseres (ved at krysslisten slettes) senest ved prosjektslutt 
31.12.09 
•	 Studiet rna vurderes og tilras av Regional komite for medisinsk forskningsetikk (REK), 
og eventuelle merknader rna f0lges. Kopi av tilradning fra personvemombudet vedlegges 
s0knaden til REK. 
•	 Informasjonsskrivet endres slik at: 
o	 det paf0res en logo 
o	 at det kommer fram at Rikshospitalet er ansvarlig for gjennomf0fing av studien 
o	 at den registrerte har rett til innsyn, retting og sletting av opplysninger 
Kontaktperson for prosjektet skal hvert tredje ar sende personvemombudet ny melding som 
bekrefter at databehandlingen skjer i overensstemmelse med opprinnelig formal og 
helseregisterlovens regler. Hvis formalet eller databehandlingen endres rna personvemombudet 
informeres om dette. Studien er registrert i Rikshospitalets offentlig tilgjengelig database over 
forsknings- og kvalitetsstudier http://forpro. 
c:\documents and settings\veingv\local settings\temporary internet files\content.ie5\i1xu915i\119733[lldoc 
Med vennlig hilsen 
(sign.)
 
Aksel Sogstad
 
Personvernombud
 
Rikshospitalet HF
 
Referanser 
l-ADM.2.6.1 Risikovurdering av informasjonssikkerhet 
I-FaRA.OS Lagring, arkivering og sletting av helse- og personopplysninger i forskningsstudier 
og kvalitetssikring 
~ 
I-FaR.4.09 Utforming av samtykke og informasjonsskriv ved ekstern og intern 
databehandlingsansvarlig 
I-FaR.ll.0.2 Mal for foresp0fsel om deltakelse i forskningsprosjekt 
~ 
c:\documents and settings\veingv\local settings\temporary internet files\conten1.ie5\ilxu915i\119733[l].doc 
I 
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Appendix 3. Informed consent 
Medisinsk klinikk 
Lipidklinikken 
RI KSHOSPITALET 
Bes0ksadr: Forskningsveien 2 B, Oslo 
Postadr Rikshospitalet HF, 0027 Oslo 
Sentralbord: 23 07 00 00 
E-post: firmapost@rikshospitaleLno 
Data: 
Foresp0rsel om deltakelse i forskningsprosjekt 
Pasientinformasjon og samtykkeerkl<ering 
Foresporsel om adelta i klinisk studie
 
Dette er et sp0rsmal til deg om a delta i studien "Alvorlig hypertriglyseridemi: Arsaker og
 
behandling". F0r du bestemmer deg for om du viI delta b0r du lese denne informasjonen n0ye.
 
Kontakt gjeme en av de ansvarlige for studien dersom du har noen sp0rsmal.
 
"va skjer hvis jeg velger adelta i studien?
 
Studien baserer seg pa a samle data fra pasientjoumaler. Hvis du velger a delta betyr det at du
 
gir tillatelse til at din pasientjoumal leses for a finne fellesnevnere for pasienter med
 
hypertriglyseridemi. Studien innebrerer ikke noen ekstra unders0kelser eller oppm0te pa
 
Lipidklinikken.
 
Bakgrunn og hensikt
 
Studien 0nsker a kartlegge de mest vanlige primrere og sekundrere underliggende arsakene
 
til alvorlig hypertriglyseridemi og hvilken type behandling som gis til pasienter med hypertriglyseridemi
 
som behandles ved Lipidklinikken, Rikshospitalet- Radiumhospitalet.
 
Det er i tillegg 0nskelig a kartlegge hvilken effekt den medikamentelle behandlingen og
 
kostbehandlingen har pa hypertriglyseridemi. Studien vil paga fra h0sten 2008 til h0sten 2009.
 
"va innebrerer studien?
 
Studien innebrerer en gjennomgang og analyse av pasientjoumaler til alle pasienter med
 
diagnosen alvorlig hypertriglyseridemi som har fatt behandling ved Lipidklinikken i perioden
 
2002-2007. Det er i tillegg 0nskelig a sende et sp0rreskjema til deltageme via posten for asamle
 
ytterligere informasjon underveis i studien. Det er opp til hver enkelt om de 0nsker asvare pa dette
 
sp0rreskjemaet.
 
"va skjer med informasjonen om deg?
 
All informasjon som innhentes fra pasientjoumalen din i forbindelse med denne studien viI bli
 
behandlet konfidensielt. InfOlmasjon og opplysninger viI bli behandlet uten navn og
 
f0dselsnummer eller andre direkte gjenkjennende opplysninger. En kode knytter deg til dine
 
opplysninger gjennom en navneliste. Det er kun autorisert personell ved Lipidklinikken som
 
er knyttet til prosjektet som har adgang til navnelisten og som kan finne tilbake til deg. Du har
 
rett til innsyn, retting og sletting av opplysninger. All informasjon og opplysninger som hentes
 
ut fra pasientjoumalene viI bli bli slettet innen slutten av 2009. Det vii ikke vrere mulig a
 
RIKSHOSPITALET
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identifisere deg i resultatene av studien nar disse publiseres.
 
Hvem vi ansker a inkludere:
 
Kvinner og menn over 18 ar med diagnosen alvorlig hypertriglyseridemi
 
(fastende triglyseridniva 2: 10 mmol/L).
 
Fordeler og ulemper med a delta i prosjektet: 
Fordeler:
 
Du bidrar til a 0ke kunnskapen om hvilke faktorer og forhold som 0ker lisikoen for
 
alvorlig hypertriglyseridemi, og hvilken behandling som er mest effektiv i forhold til denne
 
diagnosen.
 
Ulemper:
 
Det er ingen kjente ulemper el1er ubehag ved a delta i denne studien.
 
Frivillig deltakelse
 
Deltakelse er frivil1ig. Du kan nar som heIst trekke ditt samtykke til a vrere med i denne studien
 
uten a oppgi grunn for dette. Dersom du velger a ikke delta, el1er a trekke deg underveis, vii dette
 
ikke ha noen betydning for din videre oppf01ging og behandling ved Lipidklinikken. Dersom du
 
0nsker a delta, undertegner du samtykkeerklreringen pa siste side og retumerer den i den vedlagte
 
frankerte svarkonvolutten.
 
Andre viktige opplysninger
 
Etter gje1dende regler er studien blitt vurdert av Regional komite for medisinsk forskningsetikk,
 
og me1dt til Personvemombudet for forskning.
 
Ansvarhavende for prosjektet er masterstudent i emrering Ingvild Veseth
 
(e-mail: ingvild.veseth@studmed.uio.no. tlf: 99635459), og overlege Kjetil Retterst01,
 
Lipidklinikken, Rikshospitalet (e-mail: kjetil.retterstol@rikshospitalet.no ).
 
SAMTYKKEERKLJERING
 
Foresp0rsel om a delta i studien: " Alvorlig hypertriglyseridemi: Arsaker og behandling"
 
Jeg har lest informasjonen ovenfor og vii delta i studien. Jeg er inneforstatt med at jeg mlr 
som heist kan trekke meg uten a oppgi grunn, og uten at det far falger for min ordinrere 
behandling. 
Dato: Navn pi\. prosjektdeltager i blokkbokstaver Signatur 
Jeg er villig til i\. motta og svare pi\. et sp0rreskjema (sett ring rundt): JA NEI 
Dato: Navn pi\. prosjektansvarlig i blokkbokstaver Signatur 
Ii) RIKSHOSPITALET 
m:\masteroppgave\samtykkeskjema.doc 
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Appendix 4: SmartDiet questionnaire
25 spørsmål om ditt kosthold og din livsstil
Copyright: Lipidklinikken®, Medinnova, Rikshospitalet. Kopiering av dette skjemaet er ikke tillatt. 
Les spørsmålene og de angitte svarmulighetene nøye!  
Sett kryss ved det svaret som passer best med det du vanligvis spiser.   
Kostholdsvurdering  
24 poeng eller mindre: Du bør forbedre kostholdet ditt på mange punkter, for å gjøre det mer 
 helse- og hjertevennlig.
25-30 poeng: Du kan forbedre kostholdet ditt på en del punkter, slik at det blir mer
 helse- og hjertevennlig.
31 poeng eller mer: Du har sunne kostholdsvaner.
Kommentarer:
Antall poeng:  
TM
Drikk mager melk, 1/2 liter skummet, søt eller sur, 
daglig. Dersom du ikke drikker melk daglig, kan 
det føre til et for lavt inntak av kalsium.
Alle fløte- og rømmetyper inneholder mye mettet 
fett og anbefales ikke i hverdagskostholdet. 
Cultura, skummet kultur, lettmelk, ekstra lettmelk, 
skummet melk, yoghurt og Kesam (1% fett) kan 
brukes i matlaging, til sauser og dressing.
Ost er en kilde til store mengder mettet fett. Velg 
lettere eller mager ost (ost med mindre enn 10 % 
fett) til hverdags. Ikke bruk lettere ost som pålegg 
på mer enn en tredel av dagens brødskiver. Vær 
også oppmerksom på mengde og type ost du 
bruker i matlagingen.
Fett kjøtt er også en kilde til store mengder mettet 
fett. Velg kjøtt med mindre enn 10 % fett både 
som middagsmat og som pålegg. Skjær bort 
alt synlig fett, og spis minst mulig oppblandede 
kjøttprodukter. Velg for eksempel karbonadedeig 
eller kylling-/ svinekjøttdeig fremfor kjøttdeig. 
Fjern skinnet på kylling, kalkun og annet fjærkre. 
Velg skinkeprodukter fremfor salami, fårepølse og 
lignende. 
Spis alle typer fisk til middag flere ganger i uken. 
Fet fisk som makrell, sild, laks og ørret inne-
holder umettet fett (omega-3) og er derfor spesielt 
gunstig. Spis fisk som pålegg daglig. Ta i tillegg 1 
skje tran, eventuelt 2 fiskeoljekapsler, daglig året 
rundt.
Bruk gjerne majonespålegg daglig, men i mode-
rate mengder.
De fleste majonesprodukter inneholder mye olje og 
derfor mye fett (og kalorier!), men fettet er umettet 
og derfor gunstig. 
Myk plantemargarin er en god kilde til umettet fett. 
Velg typer med mer enn 
70 % umettet fett. Velg gjerne margarin med 
plantesteroler. Plantesteroler er gunstig for kole-
sterolet. 
Bruk gjerne olje, flytende eller myk plantemarga-
rin i matlagingen (velg typer med mer enn 70 % 
umettet fett). Spis mindre stekt mat. Velg heller 
kokt eller ovnsstekt mat, da vil behovet for fett i 
matlagingen reduseres. 
Grove kornprodukter er viktig i hverdagskost-
holdet. Spis mye av alle sorter fiberrike korn-
produkter. Havre er spesielt gunstig og bør brukes 
regelmessig. Brødet bør inneholde mer enn 6 gram 
fiber pr 100 g brød. Se også etter Brødskala’n på 
emballasjen. 
Husk ”5-om-dagen”. Spis minst to porsjoner frukt 
eller bær hver dag.
Fyll halve middagstallerkenen med grønnsaker, 
både rå og lettkokte. Spis grønnsaker som mellom-
måltid, som pålegg og som pynt på pålegget. Vær 
raus med porsjonene. 
Erter, bønner og linser kan med fordel spises ofte. 
 
En porsjon poteter, ris eller pasta er et fint tilbehør 
til middagen daglig.
Bruk minst mulig sukker, sukkerholdig mat og 
drikke, som kjeks, kaker, is, søtt pålegg, sukker-
godt, sjokolade, juice, nektar, saft og brus. Disse 
produktene gir ingen næringsstoffer men kan bidra 
til økt vekt. Sukker kan også øke triglyseridene. 
Nøtter og mandler inneholder gunstig umettet fett, 
men er veldig kaloririke. Bruk det derfor gjerne, 
men i begrenset mengde. Kokosnøtten og Chilli-
nøttene inneholder mye mettet fett og bør derfor 
unngås. 
Kaffebønnen inneholder fettstoffer som øker kole-
sterolet. Velg derfor pulverkaffe (inneholder ikke 
fett) eller kaffe som blir filtrert. Filteret fjerner det 
meste av fettstoffene. Husk at kaffe tilsatt melk (for 
eksempel Cafe latte, cappucino) kan være en kilde 
til mettet fett avhengig av melketypen som brukes 
og mengde kaffe som drikkes. 
Alkohol inneholder mye kalorier og kan derfor føre 
til vektøkning. Alkohol kan også øke triglyseridene. 
Eggeplommen inneholder mye kolesterol. Begrens 
inntaket til to eggeplommer per uke. Den største 
kilden til kolesterol i kostholdet er likevel matvarer 
rike på mettet fett. 
De gode rådene finner du her
Mettet fett er kolesteroløkende. Reduser derfor inntaket av matvarer med mye mettet fett. Velg i stedet 
matvarer med mye umettet fett som kan senke kolesterolet. 
Spørreskjemaet vil ikke nødvendigvis gi et komplett bilde av ditt kosthold. Du kan få mer informasjon om 
kostholdet i heftet "Kostbehandling ved høye blodlipider hos voksne" (Lipidklinikken 2006). 
Spørsmål 1-13 med unntak av spørsmål 10 er evaluert i forhold til veid kostholdsregistrering. 
Kilde: Svilaas A, Ström EC, Svilaas T, Borgejordet Å, Thoresen M, Ose L. SmartDietTM, a health educational tool. 
Reproducibility and validity of a short food questionnaire for assessment of dietary habits. Nutr Metab
Cardiovasc Dis 2002; 12: 60-70. Skjemaet er revidert i 2007.
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1. Måltidsmønster
Hvor mange måltider spiser du daglig? 1 til 2 måltider          3 måltider
                                  4 måltider                  5 eller flere måltider
2. Høyde og vekt        
Høyde:...................... cm        Vekt:.......................... kg 
Jeg ønsker å gå ned i vekt Nei Ja
Hvis ja, hvor mange kilo ønsker du å gå ned i vekt? ......................... kg  
 
3. Røyk/snus 
Røyker du?  Nei Ja Ja, selskapsrøyker 
Hvis ja, hvor mange sigaretter/piper røyker du per dag?    Antall ………………
Snuser du? Nei                    Ja              
Hvis ja, hvor mange porsjoner snuser du per dag?            Antall ………………
4. Mosjon
Hvor ofte mosjonerer du i minst 30 minutter? 
Rask gange, løping, skigåing, svømming, sykling etc.
 Sjeldnere enn 1 gang per uke eller aldri 
 1 til 2 ganger per uke 3 eller flere ganger per uke 
5. Kosttilskudd 
Bruker du kosttilskudd?             Nei Tran Fiskeoljekapsler/omega3-kapsler 
 Multivitaminpreparat Annet:................................................................
Navn:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Fødselsdato:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   Dato for besvarelsen:  . . . . . . . . . . . . . . . . . . . . . .
Navn på fastlege:  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Adresse til fastlege: . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
14. Belgvekster 
Spiser du belgvekster ukentlig?     Ja             Nei
Eksempel: hvite tomatbønner, brune bønner, kikerter, linser, erter, sukkererter. 
15. Potet, ris og pasta
Hvor mange porsjoner poteter, ris og/eller pasta spiser du daglig?
En porsjon tilsvarer 2 poteter eller 1 dl kokt ris eller 1 dl kokt pasta/spagetti
      Spiser ikke             0-1 porsjon         2 porsjoner            3 porsjoner eller fler
16. Sukker, søtt pålegg, søt drikke, kaker, kjeks og annet snacks
Bruker du mer enn 1,5 dl søt drikke daglig?   Ja             Nei
Eksempel: Saft • Brus • Fruktjuice • Nektar 
Spiser du sjokolade ukentlig?   Ja             Nei
Spiser du fløteis ukentlig?   Ja             Nei
Spiser du annet snacks som potetgull, ostepop, baconcrisp, 
tortilla chips o.l. ukentlig?  Ja             Nei 
Spiser du kake eller kjeks ukentlig?  Ja             Nei
Spiser du smågodt, seigmenn eller annet sukkergodt ukentlig?    Ja             Nei
17. Nøtter og mandler
Spiser du nøtter/mandler ukentlig? Ja              Nei
18. Kaffe
Drikker du kaffe? Ja              Nei
Hvis ja, hvilken type?:……………………………...............................        
F.eks. cappucino, café latte, kokekaffe, traktekaffe, pulverkaffe
19. Alkohol
Drikker du alkohol?                                                  Ja            Nei 
Hvis ja, hvor mange enheter drikker du til sammen hver uke?
      Mindre enn 1              1-7                8-14               Mer enn 15        
20. Egg
Hvor mange egg, inkludert i matlaging, spiser du per uke?     Antall...........................
1 enhet =
1 glass vin (125 ml)
1 glass øl (0.33 l) 
4 cl brennevin  
	 	
 
7. Fisk til middag
Hvor mange ganger i uken spiser du fisk, fiskemat og/eller fiskeretter?
Inntil en gang i uken eller aldri  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 ganger i uken  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3 eller flere ganger i uken  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Til hvor mange av disse middagene spiser du fet fisk ukentlig?                          
Antall:...........
Med fet fisk menes f.eks. ørret, laks, makrell, kveite, sild.
8. Majones, remulade og kaviar
Hvor ofte bruker du majonesprodukter, remulade og/eller kaviar på brødmaten?
Eksempler: Majones • Rekesalat • Italiensk salat • Crab-stick salat • Skagensalat • 
Frokostsalat • Remulade • Kaviar/kaviarmix mfl.
På inntil 1 brødskive i uken, eller aldri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
På 2-7 brødskiver i uken . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
På 8 eller flere brødskiver per uke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9. Smør eller margarin på brødmaten
Hvilken type bruker du oftest?
Alle typer smør • Smøregod • Bremyk • Brelett • Melange margarin • Per margarin • 
Soft margarin uten salt og melk • Letta  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Soft Flora • Soft Light • Soya margarin • Soya lett margarin •
Oliven margarin • Olivero • Solsikke margarin • Soft Ekstra  . . . . . . . . . . . . . . . . . . . . . .
Vita • Vita lett • Vita Pro-aktiv • Becel Pro-activ • Münsterland Organic Margarin  . . . . .
Bruker vanligvis ikke smør eller margarin på brødmaten  . . . . . . . . . . . . . . . . . . . . . . . . .
10. Bruker du et produkt som inneholder plantesteroler?
Bruker du produkter som inneholder plantesteroler? 
Eksempler: Vita pro-aktiv • Becel pro-aktiv • yoghurt shot              ja          nei
11. Fett i matlagingen
Hvilken type fett bruker du oftest til steking, baking, i saus, som dressing ol.?
Alle typer smør • Bremyk • Smøregod • Melange margarin • Per margarin • 
Soft Flora stekemargarin • Soya stekemargarin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Soft Flora • Soya margarin • Solsikke margarin • Oliven margarin •
Olivero • Soft Ekstra  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Olje • Flytende margarin • Vita  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Bruker vanligvis ikke fett i matlagingen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12. Brød, knekkebrød og andre kornprodukter
Hvor mange skiver brød, rundstykker eller knekkebrød spiser du daglig?  Antall:...........
Hvor mange porsjoner havregrøt, kornblanding eller andre typer frokost-
blandinger spiser du daglig?                                                                        Antall:............ 
Hvor grove kornvarer bruker du?
Spiser oftest brød, knekkebrød, kornblandinger og lignende med lite fiber, dvs
fint mel er hovedingrediensen og matvaren har mindre enn 50 % grovhet.
Eksempler: Kneippbrød • Loff • Fine rundstykker • Baguetter • Ciabatta • Lyst 
knekkebrød • Riskaker • Puffet ris • Cornflakes • Havrenøtter • Frokostkorn med 
(sjokolade, honning, sukker) m.fl. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Spiser oftest brød, knekkebrød, kornblandinger og lignende med mye fiber, dvs
sammalt mel er hovedingrediens og matvaren har mer enn 50 % grovhet.  
Eksempler: Rugbrød • Pumpernikkel • Mørke knekkebrød • Rugsprø • Fiberrik • 
Havregryn • Weetabix, Havrefras • Shredded wheat m.fl. . . . . . . . . . . . . . . . . . . . . . . . .
Spiser ikke brød, knekkebrød, eller andre kornprodukter . . . . . . . . . . . . . . . . . . . . . . . . .
13. Grønnsaker, frukt og bær
Hvor mange porsjoner grønnsaker, frukt og bær spiser du daglig?   
1 porsjon=150g som tilsvarer ca 2 gulrøtter eller ca 1 1/2 eple
Mindre enn 2 porsjoner ( < 300g )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2-4 porsjoner ( 300-600g )  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
4 porsjoner eller mer ( > 600g ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hvor mange av disse porsjonene er grønnsaker?   Antall:.......................
                                                                          Totalt antall poeng:
1. Melk (sur/søt) og yoghurt
Hvor mange små beger med yoghurt (ca 1 dl) spiser du i løpet av en uke?  Antall:.........
Hvor mange glass melk drikker/bruker du daglig?                                         Antall:.........
Hvilken type melk bruker du oftest som drikke, i matlagingen, på gryn, i grøt, i dessert, 
i kaffe/te ol.?
Helmelk • Kulturmelk • Kefir • Kaffemelk 5 % fett  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lettmelk • Cultura • Biola (syrnet lettmelk) • Ekstra Lett melk . . . . . . . . . . . . . . . . . . . . .
Skummet melk • Skummet kulturmelk • Biola bærdrikk (0,1 % fett)  . . . . . . . . . . . . . . . .
Drikker/bruker mindre enn 1 liter melk i uken eller aldri  . . . . . . . . . . . . . . . . . . . . . . . . . .
2. Fløte, rømme og lignende.
Hvilken type bruker du oftest i matlagingen, i dressing, i dip, i kaker, i kaffe/te ol.?
Kremfløte • Créme Fraiche • Seterrømme • Pisket krem . . . . . . . . . . . . . . . . . . . . . . . . .
Matfløte • Lettrømme  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kaffefløte • Ekstra lettrømme • Vikingmelk • Kesam • Matyoghurt. . . . . . . . . . . . . . . . . . . .
Bruker ikke ukentlig eller bruker aldri  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3. Ost på brødmaten, i matlaging, på pizza o.l.
Hvor mye ost som pålegg, regnet i osteskiver eller i spiseskjeer 
(for smørbar ost) spiser du daglig?                                                    Antall:................
Til hvor mange middager per uke bruker du ost? 
(eks. pizza, taco, gratinering, lasagne, i saus, i salat ol.)                   Antall:................
Hvilken type ost bruker du oftest?
Hvitost • Nøkkelost • Gudbrandsdalsost (G35) • Ekte geitost • Fløtemysost • Edamer • 
Gräddost • "Dessert oster" • Smørbare fete oster • Mozzarella • Fetaost • 
Revet pizza-/pastaost • Taffelost • Burgerost • Snøfrisk • Parmesan . . . . . . . . . . . . . . .
Lettere hvitost • Lettere nøkkelost • Lettere fløtemysost • Lettere Gudbrandsdalsost • 
Lettere smørbare oster • Mozzarella • Fetaost • Prim med vaniljesmak  . . . . . . . . . . . . .
Ost med raps og solsikkeolje • Cottage cheese • Gamalost • Pultost • 
Mager mysost • Prim • Mager prim  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Jeg bruker ost en gang i uken eller aldri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4. Kjøttpålegg
Hvilken type kjøttpålegg bruker du oftest? 
Leverpostei • Salami • Lett salami • Servelat • Fårepølse • Stabburpølse • 
Morrpølse • Haugpølse • Reinsdyrpølse • Falukorv • Fleskepølse • Sylte • Lammerull • 
Paté • Fenalår . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Kokt/røkt skinke • Hamburgerrygg • Krydderskinke Pastramiskinke • Roastbiff • 
Bankekjøtt • Kylling- og kalkunpålegg • Lett servelat • Kalverull • Spekeskinke uten 
fettrand • oljebaserte posteier (Vita/Mills, Delikat, Gilde) eller mager leverpostei  . . . . . .
Bruker ikke kjøttpålegg ukentlig eller bruker aldri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5. Kjøtt til middag
Hvilken type bruker du oftest? 
Familiedeig • Medisterdeig • Grillpølse • Wienerpølse • Kjøttpølse • Medisterpølse • 
Knakkpølse • Nakkekoteletter med fettrand • Lammekoteletter • Medisterkake • 
Wienerschnitzel  • Bacon • Flesk • Grillben • Fårekjøtt  . . . . . . . . . . . . . . . . . . . . . . . . . .
Kjøttdeig (okse, lam) • Kyllingpølse • Lettpølse • Kjøpte karbonader • Hamburger • 
Kebabkjøtt • Kjøttkaker • Kjøttpudding • Kamkoteletter med fettrand • Nakkekoteletter 
uten fettrand • Kylling, kalkun og høne med skinn • Bayonneskinke med fettrand • 
Hamburgerrygg med fettrand  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Karbonadedeig • Kjøttdeig (svin, kylling) • Biff • Filet (kylling, svin, okse, lam) • 
Viltkjøtt • Stek uten fettrand • Bogskinke • Kamkoteletter uten fettrand • Kjøtt uten 
synlig fett • Kylling, kalkun og høne uten skinn  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Jeg spiser ikke kjøtt ukentlig eller aldri  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6. Fiskepålegg
Hvor ofte har du fiskepålegg på brødmaten?
Eksempler: Laks • Makrell • Sild • Sardiner • Brisling • Tunfisk • Reker • Krabbe • 
Crab-sticks • Fiskepudding • Fiskekaker m.fl
På inntil 1 brødskive i uken, eller aldri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
På 2-4 brødskiver i uken . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
På 5 eller flere brødskiver per uke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
 
 
 
 
	 	
	 	
